Citrullinemia Type I

Mendelian MONDO:0008988 Pathograph 38 Urea Cycle Disorder Inborn Error of Metabolism

Citrullinemia type I (CTLN1) is an autosomal recessive urea cycle disorder caused by biallelic pathogenic variants in ASS1, encoding argininosuccinate synthase 1. ASS1 deficiency blocks the condensation of citrulline and aspartate to form argininosuccinate (the third enzymatic step of the urea cycle), impairing hepatic nitrogen disposal. This leads to hyperammonemia, markedly elevated plasma citrulline, low plasma arginine, and orotic aciduria. The clinical spectrum ranges from a severe neonatal-onset ("classic") form with life-threatening hyperammonemic crises to milder late-onset forms, pregnancy/postpartum-triggered presentations, and asymptomatic individuals. Acute hyperammonemia produces neurotoxicity through astrocyte glutamine accumulation, osmotic swelling, and cerebral edema. Long-term outcomes depend on residual enzyme activity, rapidity of diagnosis, and prevention of hyperammonemic events.

Ask OpenScientist

Ask a research question about Citrullinemia Type I. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
5
Pathophys.
13
Phenotypes
38
Pathograph
1
Genes
8
Treatments
2
References
1
Deep Research
👪

Inheritance

1
Autosomal recessive HP:0000007
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"CTLN1 is inherited in an autosomal recessive manner."
GeneReviews directly states the inheritance pattern for CTLN1.
⚙

Pathophysiology

5
ASS1 molecular function deficiency
Biallelic pathogenic variants in ASS1 reduce argininosuccinate synthase catalytic activity in periportal hepatocytes.
hepatocyte link
ASS1 link
argininosuccinate synthase activity link ↓ DECREASED
cytosol link
liver link
Downstream
Impaired hepatic ureagenesis due to ASS1 deficiency Reduced ASS1 function blocks citrulline-aspartate condensation and urea-cycle flux.
Show evidence (1 reference)
PMID:37485339 SUPPORT Human Clinical
"Citrullinemia type I (CTLN1) is a rare autosomal recessive inborn error of the urea cycle caused by mutations in the gene encoding the arginosuccinate synthetase (ASS1) enzyme."
Supports ASS1 molecular deficiency as the initiating defect.
Impaired hepatic ureagenesis due to ASS1 deficiency
Reduced ASS1 activity blocks conversion of citrulline and aspartate to argininosuccinate in periportal hepatocytes. This leads to accumulation of upstream substrates (citrulline, ammonia) and failure to detoxify nitrogen, causing hyperammonemia. The severity of the metabolic block correlates with residual ASS1 enzyme activity, which is determined by the specific pathogenic variants.
urea cycle link arginine biosynthetic process link
Downstream
Ammonia Failed ureagenesis leaves nitrogen as circulating ammonia.
Citrulline Blocked argininosuccinate synthesis causes upstream citrulline accumulation.
Argininosuccinate Blocked ASS1 activity prevents formation of argininosuccinate from citrulline and aspartate.
Arginine Reduced ASS1-dependent argininosuccinate formation limits downstream arginine synthesis, producing low-to-normal plasma arginine.
Hyperammonemia Accumulated ammonia manifests clinically as hyperammonemia.
Respiratory alkalosis Severe hyperammonemia in neonatal urea-cycle emergencies can cause tachypnea and respiratory alkalosis.
Hyperammonemic neurotoxicity via astrocyte glutamine-osmotic injury Ammonia accumulation from impaired ureagenesis drives CNS glutamine osmotic injury.
Show evidence (2 references)
PMID:39649700 SUPPORT Human Clinical
"the patient exhibited significantly elevated blood ammonia levels (655 μmol/L; normal reference: 10-30 μmol/L) and increased citrulline concentrations (936 μmol/L; normal reference: 5-25 μmol/L)"
Quantitative case data demonstrating the magnitude of ammonia and citrulline accumulation in severe CTLN1.
PMID:20301631 SUPPORT Other
"elevated plasma ammonia concentration (>150 µmol/L; may range to ≥2000-3000 µmol/L), elevated plasma citrulline concentration (usually >500 µmol/L), and absent argininosuccinate"
GeneReviews anchors the blocked ASS1 reaction by identifying absent argininosuccinate alongside elevated ammonia and citrulline.
Hyperammonemic neurotoxicity via astrocyte glutamine-osmotic injury
During hyperammonemic crises, systemic ammonia crosses into the CNS where astrocytes detoxify ammonia by converting it to glutamine. Rapid intracellular glutamine accumulation increases osmolarity, causing astrocyte swelling, inflammatory cascades, and cerebral edema. This mechanism connects the hepatic metabolic defect to acute brain pathology including lethargy, seizures, increased intracranial pressure, and coma.
astrocyte link
glutamine biosynthetic process link cellular response to nitrogen compound link cellular response to osmotic stress link
brain link
Downstream
Cerebral edema Glutamine-driven osmotic injury manifests as increased intracranial pressure and cerebral edema.
Glutamine Astrocytic ammonia detoxification during hyperammonemic crises produces glutamine accumulation.
Encephalopathy CNS ammonia/glutamine toxicity produces acute hyperammonemic encephalopathy.
Lethargy Early hyperammonemic encephalopathy manifests as progressive lethargy.
Poor feeding Acute hyperammonemic encephalopathy causes poor feeding in neonatal crises.
Vomiting Vomiting occurs as part of the neonatal hyperammonemic encephalopathy syndrome.
Seizures Severe hyperammonemic CNS injury can produce seizures.
Coma Untreated hyperammonemic encephalopathy can progress to loss of consciousness and coma.
Spasticity Increased neuromuscular tone and spasticity occur in severe hyperammonemic crises.
Intellectual disability Promptly treated severe neonatal disease may still leave significant neurologic deficits.
Global developmental delay Severe neonatal hyperammonemic injury can leave developmental and neurologic deficits in survivors.
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death."
GeneReviews entry describes the cascade from ammonia and glutamine accumulation to cerebral edema and neurological decline.
Genotype-to-phenotype correlation through residual ASS1 activity
The severity spectrum of CTLN1 (classic neonatal, late-onset, pregnancy-triggered, asymptomatic) is determined by residual ASS1 enzyme activity. Pathogenic variants affect the citrulline-binding site, oligomerization helix stability, protein expression levels, or cause premature truncation. Variants with less than 2% of wild-type activity typically produce classic neonatal presentations, while hypomorphic variants may allow milder or late-onset disease.
ASS1 link
protein tetramerization link
argininosuccinate synthase activity link
Downstream
Impaired hepatic ureagenesis due to ASS1 deficiency Residual enzyme activity determines the depth of the urea-cycle flux defect.
Secondary metabolic derangements during catabolic stress Residual ASS1 activity sets crisis threshold under catabolic nitrogen load.
Show evidence (2 references)
PMID:39649700 SUPPORT Computational
"the C- terminal helix domain of the mutant protein structure, which was an important structure for ASS1 protein to form protein tetramers, was indeed more unstable than that of the wild-type protein structure."
In silico analysis showing C-terminal helix instability disrupts ASS1 tetramerization.
PMID:38927689 SUPPORT Human Clinical
"The p.Arg265Cys variant leads to enzyme deficiency, whereas p.Gly390Arg renders the enzyme inactive."
Demonstrates that different ASS1 variants produce different degrees of enzyme impairment.
Secondary metabolic derangements during catabolic stress
Although baseline ureagenesis is impaired, acute hyperammonemic crises are precipitated when nitrogen production exceeds residual detoxification capacity during illness or catabolism. This produces abrupt rises in ammonia and citrulline, orotic aciduria from secondary pyrimidine pathway perturbation, and depleted arginine.
urea cycle link pyrimidine nucleotide biosynthetic process link
Downstream
Hyperammonemia Catabolic nitrogen load can exceed residual ASS1-dependent ureagenesis and trigger hyperammonemia.
Orotic acid During metabolic crises, secondary perturbation of ornithine transcarbamylase/carbamoyl phosphate handling can produce detectable urinary orotic acid.
Failure to thrive Recurrent crises and chronic dietary restriction can impair growth, with transplant-associated metabolic stability improving growth outcomes.
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"Agents/circumstances to avoid: Excessive protein intake, prolonged fasting, and obvious exposure to communicable diseases."
GeneReviews identifies excess protein, fasting, and infectious exposure as avoidable triggers for metabolic decompensation.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Citrullinemia Type I Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

13
Digestive 2
Poor feeding VERY_FREQUENT Feeding difficulties (HP:0011968)
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"Shortly thereafter, they develop hyperammonemia and become progressively lethargic, feed poorly, often vomit, and may develop signs of increased intracranial pressure (ICP)."
GeneReviews directly describes poor feeding in neonatal CTLN1.
Vomiting FREQUENT Vomiting (HP:0002013)
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"Shortly thereafter, they develop hyperammonemia and become progressively lethargic, feed poorly, often vomit, and may develop signs of increased intracranial pressure (ICP)."
GeneReviews directly lists vomiting in neonatal CTLN1 decompensation.
Metabolism 3
Hyperammonemia VERY_FREQUENT Hyperammonemia (HP:0001987)
Sequelae: Encephalopathy Cerebral edema Respiratory alkalosis
Show evidence (2 references)
PMID:39649700 SUPPORT Human Clinical
"the patient exhibited significantly elevated blood ammonia levels (655 μmol/L; normal reference: 10-30 μmol/L)"
Case report with quantitative ammonia data demonstrating severe hyperammonemia in CTLN1.
PMID:40218931 SUPPORT Human Clinical
"The median ammonia level in deceased patients was higher at 1058 µmol/L (IQR 410-1793) than in survivors at 294 µmol/L (IQR 71-494)"
Registry data on ammonia as a prognostic marker in UCD patients.
Cerebral edema FREQUENT Cerebral edema (HP:0002181)
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death."
GeneReviews describes increased ICP (intracranial pressure) as a direct consequence of hyperammonemia.
Respiratory alkalosis OCCASIONAL Respiratory alkalosis (HP:0001950)
Show evidence (1 reference)
PMID:33113778 SUPPORT Human Clinical
"This report aims to highlight the importance of suspecting urea cycle disorders in newborns with aspecific signs of hyperammonemia and respiratory alkalosis"
Human newborn UCD cases support respiratory alkalosis as a hyperammonemic crisis feature relevant to CTLN1.
Musculoskeletal 1
Spasticity OCCASIONAL Spasticity (HP:0001257)
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death."
GeneReviews lists spasticity among the neurological manifestations of hyperammonemic crises.
Nervous System 6
Encephalopathy VERY_FREQUENT Encephalopathy (HP:0001298)
Sequelae: Lethargy Poor feeding Vomiting Seizures Spasticity Coma
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death."
GeneReviews describes hyperammonemic encephalopathy progression from lethargy to coma and death.
Seizures FREQUENT Seizure (HP:0001250)
Show evidence (2 references)
PMID:39649700 SUPPORT Human Clinical
"The patient was characterized by severe clinical manifestations, including poor responsiveness, lethargy, convulsions, and cardiac arrest."
Case report documenting convulsions as part of severe neonatal CTLN1 presentation.
PMID:20301631 SUPPORT Other
"Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death."
GeneReviews confirms seizures as a manifestation of hyperammonemic encephalopathy.
Lethargy VERY_FREQUENT Lethargy (HP:0001254)
Show evidence (1 reference)
PMID:39649700 SUPPORT Human Clinical
"The patient was characterized by severe clinical manifestations, including poor responsiveness, lethargy, convulsions, and cardiac arrest."
Case report documenting lethargy as a presenting feature of severe neonatal CTLN1.
Intellectual disability FREQUENT Intellectual disability (HP:0001249)
Show evidence (1 reference)
PMID:40218931 SUPPORT Human Clinical
"Neurological impairment occurred in 44% of patients, with worse neurological outcomes observed in patients with argininosuccinate lyase deficiency, arginase 1 deficiency, hyperornithinemia-hyperammonemia-homocitrullinuria, EO presentations, pre-2014 diagnosis, and patients with higher levels of..."
Registry data showing neurological impairment in 44% of UCD patients.
Global developmental delay FREQUENT Global developmental delay (HP:0001263)
Show evidence (1 reference)
PMID:40218931 SUPPORT Human Clinical
"Neurological impairment occurred in 44% of patients"
High rate of neurological impairment in UCD patients supports developmental delay as a common outcome.
Coma OCCASIONAL Coma (HP:0001259)
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death."
Loss of consciousness progressing to coma is described as part of the hyperammonemic crisis cascade.
Growth 1
Failure to thrive FREQUENT Failure to thrive (HP:0001508)
Show evidence (1 reference)
PMID:38054409 SUPPORT Human Clinical
"LTx enabled metabolic stability by prevention of further hyperammonemic events after transplantation and was associated with a more favorable growth outcome compared with individuals remaining under MM."
Growth improvement after liver transplant implies growth impairment during medical management.
🧬

Genetic Associations

1
ASS1 pathogenic variants
Autosomal recessive
Show evidence (4 references)
PMID:39649700 SUPPORT Computational
"the C- terminal helix domain of the mutant protein structure, which was an important structure for ASS1 protein to form protein tetramers, was indeed more unstable than that of the wild-type protein structure."
Structural analysis demonstrating how specific variants disrupt ASS1 tetramer stability.
PMID:37485339 SUPPORT Human Clinical
"Both c.649_651del (p.P217del) and c.1048C>T (p.Q350*) showed a highly significant reduction in enzyme activity, while c.-4C>T had no effect."
Functional studies demonstrating variable residual activity across different ASS1 variant types.
PMID:39449289 SUPPORT Other
"LNP-formulated mRNA therapy has been assayed preclinically for citrullinemia type I (CTLN1), adolescent and adult citrin deficiency, argininosuccinic aciduria, arginase deficiency and ornithine transcarbamylase deficiency"
Review noting nonsense mutations in approximately 7-10% of ASS1, relevant for therapeutic targeting.
+ 1 more reference
💊

Treatments

8
Protein-restricted diet with essential amino acid supplementation
Action: dietary intervention MAXO:0000088
Long-term dietary management centers on restriction of protein intake to reduce nitrogen load while providing essential amino acids via specialized formula. This is the cornerstone of chronic CTLN1 management. Liver transplantation eliminates the need for protein restriction.
Mechanism Target:
INHIBITS Secondary metabolic derangements during catabolic stress — Protein restriction lowers exogenous nitrogen load and reduces the risk that residual ureagenesis will be overwhelmed.
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"Daily routine treatment in those who have not undergone a liver transplantation includes lifelong protein restriction in conjunction with a metabolic nutritionist; nitrogen scavenger medications; arginine supplementation;"
GeneReviews identifies lifelong protein restriction as a routine treatment used to prevent metabolic decompensation.
Show evidence (1 reference)
PMID:38054409 SUPPORT Human Clinical
"LTx enabled metabolic stability without further need of protein restriction or nitrogen-scavenging therapy"
Confirms that protein restriction is standard pre-transplant medical management for UCDs.
Nitrogen scavenger therapy
Action: nitrogen scavenger therapy Ontology label: Pharmacotherapy NCIT:C15986
Agent: sodium benzoate ↗ sodium phenylbutyrate ↗ glycerol phenylbutyrate ↗
Sodium benzoate, sodium phenylbutyrate, or glycerol phenylbutyrate are used to promote alternative nitrogen disposal pathways. These agents conjugate with glycine or glutamine to form hippurate or phenylacetylglutamine, which are renally excreted, thus bypassing the blocked urea cycle.
Mechanism Target:
BYPASSES Impaired hepatic ureagenesis due to ASS1 deficiency — Scavenger drugs bypass the compromised urea cycle by providing alternative nitrogen-disposal routes.
Show evidence (1 reference)
PMID:27860485 SUPPORT Other
"Ammonia-scavenging drugs, benzoate and phenylacetate (PA)/phenylbutyrate (PB), modulate hepatic nitrogen metabolism mainly by providing alternative pathways for nitrogen disposal."
The review directly supports a bypass edge from scavenger therapy around the blocked urea cycle through alternative nitrogen disposal.
Target Phenotypes: Hyperammonemia ↗
Show evidence (2 references)
PMID:38054409 SUPPORT Human Clinical
"LTx enabled metabolic stability without further need of protein restriction or nitrogen-scavenging therapy"
Confirms nitrogen scavenger therapy as part of standard medical management for UCDs prior to transplant.
PMID:27860485 SUPPORT Other
"Ammonia-scavenging drugs, benzoate and phenylacetate (PA)/phenylbutyrate (PB), modulate hepatic nitrogen metabolism mainly by providing alternative pathways for nitrogen disposal."
Review evidence defines the nitrogen-scavenger mechanism as alternative nitrogen disposal.
Arginine supplementation
Action: nutritional supplementation MAXO:0000106
Agent: L-arginine ↗
Arginine supplementation is required because the ASS1 block prevents endogenous arginine synthesis. Supplemental arginine also helps drive residual urea cycle flux and supports protein synthesis.
Mechanism Target:
MODULATES Impaired hepatic ureagenesis due to ASS1 deficiency — Arginine supplementation provides the downstream urea-cycle amino acid and increases measured urea synthesis in vivo.
Show evidence (1 reference)
PMID:10869432 SUPPORT Human Clinical
"Urea synthesis is altered by alternative route medications and arginine supplementation to the degree that is to be expected from theory."
Human isotope-flux data support a mechanism link from arginine supplementation to altered urea-cycle flux.
Show evidence (2 references)
PMID:20301631 SUPPORT Other
"Daily routine treatment in those who have not undergone a liver transplantation includes lifelong protein restriction in conjunction with a metabolic nutritionist; nitrogen scavenger medications; arginine supplementation;"
GeneReviews directly states arginine supplementation is part of standard CTLN1 management.
PMID:10869432 SUPPORT Human Clinical
"Administration of Ucephan lowered, and arginine increased, urea synthesis to the degree predicted from their respective rates of metabolism."
Stable-isotope human data support arginine supplementation as a modifier of urea synthesis in urea-cycle patients.
Acute crisis management
Action: supportive care MAXO:0000950
Emergency management of hyperammonemic crises includes cessation of protein intake (maximum 48 hours), high-calorie glucose infusion to reverse catabolism, intravenous nitrogen scavengers, and escalation to continuous renal replacement therapy (dialysis) when ammonia exceeds 500 umol/L.
Mechanism Target:
INHIBITS Hyperammonemic neurotoxicity via astrocyte glutamine-osmotic injury — Acute crisis therapy rapidly lowers ammonia and reverses catabolism to prevent the CNS glutamine-osmotic injury cascade.
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"Acute inpatient treatment of a metabolic crisis includes addressing hyperammonemia through withholding of all protein intake for a maximum of 24 to 28 hours; pharmacologic nitrogen scavenger therapy; and consideration of dialysis"
GeneReviews directly links acute crisis therapy to rapid hyperammonemia management.
Show evidence (2 references)
PMID:20301631 SUPPORT Other
"Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death."
GeneReviews emphasizes the need for prompt intervention during hyperammonemic crises.
PMID:40218931 SUPPORT Human Clinical
"EO cases presented a higher mortality rate (35.8%) than late-onset (LO) cases (7.1%)"
High mortality in early-onset cases underscores the importance of acute crisis management.
Liver transplantation
Action: organ transplantation MAXO:0010039
Liver transplantation is the only established curative intervention at the metabolic level for CTLN1. It provides metabolic stability by restoring hepatic ASS1 activity, preventing further hyperammonemic events, and allowing liberalization of protein intake. Five-year patient survival exceeds 90%. However, pre-existing neurocognitive impairment does not improve after transplantation.
Mechanism Target:
RESTORES ASS1 molecular function deficiency — Liver transplantation replaces the deficient hepatic urea-cycle capacity and prevents further hyperammonemic events.
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"Liver transplantation is the only known curative therapy and eliminates the need for dietary restriction."
GeneReviews supports transplantation as the metabolic-level corrective intervention for CTLN1.
Show evidence (2 references)
PMID:38054409 SUPPORT Human Clinical
"LTx enabled metabolic stability by prevention of further hyperammonemic events after transplantation and was associated with a more favorable growth outcome compared with individuals remaining under MM."
Severity-adjusted analysis demonstrating metabolic stability and growth benefit after liver transplant in UCDs.
PMID:40218931 SUPPORT Human Clinical
"Among transplanted patients (20.6%), survival was 95.2%, with no significant neurological differences compared to non-transplanted patients."
Registry data showing high transplant survival but persistent neurological challenges.
Newborn screening
Action: disease screening MAXO:0000124
CTLN1 is detectable by newborn screening via tandem mass spectrometry using elevated citrulline as the primary marker. Early detection enables treatment initiation before clinical decompensation and is associated with improved survival and reduced neurological impairment.
Target Phenotypes: Hyperammonemia ↗ Global developmental delay ↗
Show evidence (1 reference)
PMID:40218931 SUPPORT Human Clinical
"Diagnosis through NBS improved survival and reduced neurological impairment compared to symptomatic diagnosis."
Registry evidence that newborn screening improves outcomes in UCDs.
Genetic counseling
Action: genetic counseling MAXO:0000079
Genetic counseling for affected families, including discussion of autosomal recessive inheritance, 25% recurrence risk for carrier parents, prenatal testing options, and carrier testing for at-risk relatives.
Mechanism Target:
MODULATES ASS1 molecular function deficiency — Counseling uses the confirmed ASS1 molecular etiology to address recurrence risk, carrier testing, and prenatal testing rather than directly altering enzyme activity.
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"Carrier testing for at-risk relatives and prenatal testing for a pregnancy at increased risk are possible if the pathogenic variants in the family are known."
GeneReviews supports variant-informed genetic counseling for families with CTLN1.
Show evidence (1 reference)
PMID:37485339 SUPPORT Human Clinical
"Molecular genetic testing is critical for patient diagnosis."
Genetic testing is essential for CTLN1, supporting the role of genetic counseling.
Emerging RNA therapeutics
Action: Pharmacotherapy NCIT:C15986
LNP-formulated mRNA therapy has been assayed preclinically for CTLN1, representing an emerging disease-modifying strategy for liver-targeted gene correction. This approach could potentially provide metabolic correction without transplantation.
Mechanism Target:
RESTORES ASS1 molecular function deficiency — Liver-targeted ASS1 mRNA replacement would restore the deficient enzyme activity upstream of the urea-cycle block.
Show evidence (1 reference)
PMID:39449289 SUPPORT Other
"LNP-formulated mRNA therapy has been assayed preclinically for citrullinemia type I (CTLN1), adolescent and adult citrin deficiency, argininosuccinic aciduria, arginase deficiency and ornithine transcarbamylase deficiency"
The review identifies preclinical CTLN1 mRNA therapy, supporting a restorative target mechanism.
Show evidence (1 reference)
PMID:39449289 SUPPORT Other
"LNP-formulated mRNA therapy has been assayed preclinically for citrullinemia type I (CTLN1), adolescent and adult citrin deficiency, argininosuccinic aciduria, arginase deficiency and ornithine transcarbamylase deficiency"
Review documenting preclinical mRNA therapy development specifically for CTLN1.
🔬

Biochemical Markers

6
Citrulline (INCREASED)
Context: Markedly elevated plasma citrulline is the defining biochemical hallmark of CTLN1. In classic disease, citrulline can reach 2000-5000 umol/L (normal less than 60 umol/L). This is the primary marker on newborn screening.
Pathograph Readouts
Readout Of Impaired hepatic ureagenesis due to ASS1 deficiency Positive Diagnostic
Markedly elevated citrulline reports the blocked ASS1 step upstream of argininosuccinate formation.
Show evidence (2 references)
PMID:20301631 SUPPORT Other
"elevated plasma citrulline concentration (usually >500 µmol/L)"
GeneReviews gives elevated plasma citrulline as a diagnostic biochemical feature of CTLN1.
PMID:39649700 SUPPORT Human Clinical
"increased citrulline concentrations (936 μmol/L; normal reference: 5-25 μmol/L)"
Quantitative case data support markedly increased citrulline.
Ammonia (INCREASED)
Context: Elevated blood ammonia results from impaired ureagenesis. During acute crises, ammonia can exceed 500-1000 umol/L. Diagnostic ammonia levels are a key prognostic marker; deceased UCD patients had median ammonia of 1058 umol/L versus 294 umol/L in survivors.
Pathograph Readouts
Readout Of Impaired hepatic ureagenesis due to ASS1 deficiency Positive Diagnostic
Elevated ammonia reports failed hepatic nitrogen disposal through the urea cycle.
Show evidence (2 references)
PMID:39649700 SUPPORT Human Clinical
"the patient exhibited significantly elevated blood ammonia levels (655 μmol/L; normal reference: 10-30 μmol/L)"
Quantitative demonstration of severe hyperammonemia in a CTLN1 case.
PMID:40218931 SUPPORT Human Clinical
"The median ammonia level in deceased patients was higher at 1058 µmol/L (IQR 410-1793) than in survivors at 294 µmol/L (IQR 71-494)"
Registry data establishing ammonia as a prognostic marker.
Arginine (DECREASED)
Context: Low plasma arginine is a secondary biochemical feature reflecting the inability to synthesize argininosuccinate, the immediate precursor of arginine via argininosuccinate lyase. Arginine supplementation is part of standard management.
Pathograph Readouts
Readout Of Impaired hepatic ureagenesis due to ASS1 deficiency Negative Diagnostic
Low-to-normal arginine is interpreted together with elevated citrulline and absent argininosuccinate as part of the ASS1-block biochemical pattern.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1458/?report=printable SUPPORT Other
"Plasma amino acids analysis demonstrating elevated citrulline, absent argininosuccinate, with low-to-normal arginine and ornithine levels"
Full GeneReviews diagnostic text supports low-to-normal arginine as a biochemical readout of the ASS1 urea-cycle block.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1458/?report=printable SUPPORT Other
"Plasma amino acids analysis demonstrating elevated citrulline, absent argininosuccinate, with low-to-normal arginine and ornithine levels"
Full GeneReviews diagnostic text directly supports low-to-normal plasma arginine in CTLN1.
Argininosuccinate (DECREASED)
Context: Absent or markedly reduced argininosuccinate is the immediate biochemical consequence of the ASS1 block, since argininosuccinate synthase normally condenses citrulline and aspartate to form argininosuccinate.
Pathograph Readouts
Readout Of Impaired hepatic ureagenesis due to ASS1 deficiency Negative Diagnostic
Absent argininosuccinate directly reports failure of ASS1-mediated citrulline-aspartate condensation.
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"elevated plasma ammonia concentration (>150 µmol/L; may range to ≥2000-3000 µmol/L), elevated plasma citrulline concentration (usually >500 µmol/L), and absent argininosuccinate"
GeneReviews lists absent argininosuccinate as part of the diagnostic biochemical pattern of CTLN1.
Orotic acid (INCREASED)
Context: Elevated urinary orotic acid (orotic aciduria) is a secondary marker reflecting accumulation of carbamoyl phosphate that is diverted into the pyrimidine synthesis pathway when ureagenesis is blocked.
Pathograph Readouts
Readout Of Secondary metabolic derangements during catabolic stress Positive Diagnostic
Detectable urinary orotic acid during crises reports secondary pyrimidine-pathway diversion in the decompensated urea-cycle state.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1458/?report=printable SUPPORT Other
"Possibly normal urine organic analysis, although orotic acid may be detected as part of urinary organic acid analysis by gas chromatography/mass spectrometry, especially during metabolic crises."
Full GeneReviews diagnostic text supports urinary orotic acid as a crisis-associated readout.
Show evidence (1 reference)
url:https://www.ncbi.nlm.nih.gov/books/NBK1458/?report=printable SUPPORT Other
"Possibly normal urine organic analysis, although orotic acid may be detected as part of urinary organic acid analysis by gas chromatography/mass spectrometry, especially during metabolic crises."
Full GeneReviews diagnostic text directly supports orotic acid detection in CTLN1, especially during metabolic crises.
Glutamine (INCREASED)
Context: Elevated plasma and brain glutamine reflects astrocytic ammonia detoxification. Glutamine accumulation in astrocytes is the direct driver of osmotic swelling and cerebral edema during hyperammonemic crises.
Pathograph Readouts
Readout Of Hyperammonemic neurotoxicity via astrocyte glutamine-osmotic injury Positive Diagnostic
Elevated glutamine reports ammonia detoxification and the osmotic neurotoxicity branch during hyperammonemic crises.
Show evidence (1 reference)
PMID:20301631 SUPPORT Other
"Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death."
GeneReviews identifies glutamine as a toxic metabolite that accumulates in CTLN1.
{ }

Source YAML

click to show 
name: Citrullinemia Type I
category: Mendelian
creation_date: '2025-06-12T20:16:27Z'
updated_date: '2026-05-19T15:46:27Z'
synonyms:
- Classic citrullinemia
- CTLN1
- Argininosuccinate synthetase deficiency
- ASS1 deficiency
- Argininosuccinic acid synthetase deficiency
description: 'Citrullinemia type I (CTLN1) is an autosomal recessive urea cycle disorder caused by biallelic pathogenic variants in ASS1, encoding argininosuccinate synthase 1. ASS1 deficiency blocks the condensation of citrulline and aspartate to form argininosuccinate (the third enzymatic step of the urea cycle), impairing hepatic nitrogen disposal. This leads to hyperammonemia, markedly elevated plasma citrulline, low plasma arginine, and orotic aciduria. The clinical spectrum ranges from a severe neonatal-onset ("classic") form with life-threatening hyperammonemic crises to milder late-onset forms, pregnancy/postpartum-triggered presentations, and asymptomatic individuals. Acute hyperammonemia produces neurotoxicity through astrocyte glutamine accumulation, osmotic swelling, and cerebral edema. Long-term outcomes depend on residual enzyme activity, rapidity of diagnosis, and prevention of hyperammonemic events.

  '
disease_term:
  preferred_term: citrullinemia type I
  term:
    id: MONDO:0008988
    label: citrullinemia type I
parents:
- Urea Cycle Disorder
- Inborn Error of Metabolism
prevalence:
- evidence:
  - reference: PMID:40218931
    reference_title: "Understanding the Natural History and the Effects of Current Therapeutic Strategies on Urea Cycle Disorders: Insights from the UCD Spanish Registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The incidence of UCD in Spain over the past decade was 1:36,063 births. The most common defects were ornithine transcarbamylase deficiency (OTCD) and argininosuccinate synthetase deficiency.
    explanation: Provides incidence data for UCDs in Spain and identifies ASS1 deficiency as the second most common UCD.
  notes: 'The most common defects in the Spanish UCD registry were ornithine transcarbamylase deficiency and argininosuccinate synthetase deficiency. The incidence of all UCDs in Spain over the past decade was approximately 1 in 36,063 births.

    '
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: CTLN1 is inherited in an autosomal recessive manner.
    explanation: GeneReviews directly states the inheritance pattern for CTLN1.
pathophysiology:
- name: ASS1 molecular function deficiency
  description: 'Biallelic pathogenic variants in ASS1 reduce argininosuccinate synthase catalytic activity in periportal hepatocytes.

    '
  genes:
  - preferred_term: ASS1
    term:
      id: hgnc:758
      label: ASS1
  molecular_functions:
  - preferred_term: argininosuccinate synthase activity
    term:
      id: GO:0004055
      label: argininosuccinate synthase activity
    modifier: DECREASED
  cellular_components:
  - preferred_term: cytosol
    term:
      id: GO:0005829
      label: cytosol
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:37485339
    reference_title: "Functional identification of two novel variants and a hypomorphic variant in ASS1 from patients with Citrullinemia type I."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Citrullinemia type I (CTLN1) is a rare autosomal recessive inborn error of the urea cycle caused by mutations in the gene encoding the arginosuccinate synthetase (ASS1) enzyme.
    explanation: Supports ASS1 molecular deficiency as the initiating defect.
  downstream:
  - target: Impaired hepatic ureagenesis due to ASS1 deficiency
    description: Reduced ASS1 function blocks citrulline-aspartate condensation and urea-cycle flux.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37485339
      reference_title: "Functional identification of two novel variants and a hypomorphic variant in ASS1 from patients with Citrullinemia type I."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Citrullinemia type I (CTLN1) is a rare autosomal recessive inborn error of the urea cycle caused by mutations in the gene encoding the arginosuccinate synthetase (ASS1) enzyme.
      explanation: The cited study identifies ASS1 enzyme disruption as the urea-cycle defect underlying CTLN1.
- name: Impaired hepatic ureagenesis due to ASS1 deficiency
  description: 'Reduced ASS1 activity blocks conversion of citrulline and aspartate to argininosuccinate in periportal hepatocytes. This leads to accumulation of upstream substrates (citrulline, ammonia) and failure to detoxify nitrogen, causing hyperammonemia. The severity of the metabolic block correlates with residual ASS1 enzyme activity, which is determined by the specific pathogenic variants.

    '
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
  - preferred_term: arginine biosynthetic process
    term:
      id: GO:0006526
      label: L-arginine biosynthetic process
  chemical_entities:
  - preferred_term: ammonia
    term:
      id: CHEBI:16134
      label: ammonia
    modifier: INCREASED
  - preferred_term: citrulline
    term:
      id: CHEBI:18211
      label: citrulline
    modifier: INCREASED
  - preferred_term: argininosuccinate
    term:
      id: CHEBI:15682
      label: (N(omega)-L-arginino)succinic acid
    modifier: DECREASED
  - preferred_term: L-arginine
    term:
      id: CHEBI:16467
      label: L-arginine
    modifier: DECREASED
  evidence:
  - reference: PMID:39649700
    reference_title: "Visualization of argininosuccinate synthetase by in silico analysis: novel insights into citrullinemia type I disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'the patient exhibited significantly elevated blood ammonia levels (655 μmol/L; normal reference: 10-30 μmol/L) and increased citrulline concentrations (936 μmol/L; normal reference: 5-25 μmol/L)'
    explanation: Quantitative case data demonstrating the magnitude of ammonia and citrulline accumulation in severe CTLN1.
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: elevated plasma ammonia concentration (>150 µmol/L; may range to ≥2000-3000 µmol/L), elevated plasma citrulline concentration (usually >500 µmol/L), and absent argininosuccinate
    explanation: GeneReviews anchors the blocked ASS1 reaction by identifying absent argininosuccinate alongside elevated ammonia and citrulline.
  downstream:
  - target: Ammonia
    description: Failed ureagenesis leaves nitrogen as circulating ammonia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39649700
      reference_title: "Visualization of argininosuccinate synthetase by in silico analysis: novel insights into citrullinemia type I disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'the patient exhibited significantly elevated blood ammonia levels (655 μmol/L; normal reference: 10-30 μmol/L)'
      explanation: Quantitative CTLN1 case data support ammonia accumulation downstream of impaired ASS1-dependent ureagenesis.
  - target: Citrulline
    description: Blocked argininosuccinate synthesis causes upstream citrulline accumulation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39649700
      reference_title: "Visualization of argininosuccinate synthetase by in silico analysis: novel insights into citrullinemia type I disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'increased citrulline concentrations (936 μmol/L; normal reference: 5-25 μmol/L)'
      explanation: Quantitative CTLN1 case data support citrulline accumulation downstream of the ASS1 block.
  - target: Argininosuccinate
    description: Blocked ASS1 activity prevents formation of argininosuccinate from citrulline and aspartate.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: elevated plasma ammonia concentration (>150 µmol/L; may range to ≥2000-3000 µmol/L), elevated plasma citrulline concentration (usually >500 µmol/L), and absent argininosuccinate
      explanation: GeneReviews lists absent argininosuccinate as part of the CTLN1 diagnostic biochemical pattern.
  - target: Arginine
    description: Reduced ASS1-dependent argininosuccinate formation limits downstream arginine synthesis, producing low-to-normal plasma arginine.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Argininosuccinate lyase normally converts argininosuccinate downstream to arginine.
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK1458/?report=printable'
      reference_title: "Citrullinemia Type I - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Plasma amino acids analysis demonstrating elevated citrulline, absent argininosuccinate, with low-to-normal arginine and ornithine levels
      explanation: Full GeneReviews diagnostic text connects the ASS1 biochemical pattern to low-to-normal arginine.
  - target: Hyperammonemia
    description: Accumulated ammonia manifests clinically as hyperammonemia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:39649700
      reference_title: "Visualization of argininosuccinate synthetase by in silico analysis: novel insights into citrullinemia type I disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: 'the patient exhibited significantly elevated blood ammonia levels (655 μmol/L; normal reference: 10-30 μmol/L)'
      explanation: The same quantitative case data directly support hyperammonemia as the clinical expression of ammonia accumulation.
  - target: Respiratory alkalosis
    description: >-
      Severe hyperammonemia in neonatal urea-cycle emergencies can cause
      tachypnea and respiratory alkalosis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - ammonia-associated central respiratory stimulation with hypocapnia
    evidence:
    - reference: PMID:33113778
      reference_title: "Irritability, Poor Feeding and Respiratory Alkalosis in Newborns: Think about Metabolic Emergencies. A Brief Summary of Hyperammonemia Management."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: |-
        Their first gas analysis revealed respiratory alkalosis.
        Hyperammonemia was confirmed, and three different enzymatic blocks in the urea
        cycle were diagnosed.
      explanation: >-
        Newborn urea-cycle disorder cases support respiratory alkalosis as an
        acute hyperammonemic presentation.
  - target: Hyperammonemic neurotoxicity via astrocyte glutamine-osmotic injury
    description: Ammonia accumulation from impaired ureagenesis drives CNS glutamine osmotic injury.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Ammonia crosses into the CNS and is detoxified to glutamine by astrocytes.
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
      explanation: GeneReviews links hyperammonemia and glutamine accumulation to the neurologic crisis cascade.
- name: Hyperammonemic neurotoxicity via astrocyte glutamine-osmotic injury
  description: 'During hyperammonemic crises, systemic ammonia crosses into the CNS where astrocytes detoxify ammonia by converting it to glutamine. Rapid intracellular glutamine accumulation increases osmolarity, causing astrocyte swelling, inflammatory cascades, and cerebral edema. This mechanism connects the hepatic metabolic defect to acute brain pathology including lethargy, seizures, increased intracranial pressure, and coma.

    '
  biological_processes:
  - preferred_term: glutamine biosynthetic process
    term:
      id: GO:1901704
      label: L-glutamine biosynthetic process
  - preferred_term: cellular response to nitrogen compound
    term:
      id: GO:1901699
      label: cellular response to nitrogen compound
  - preferred_term: cellular response to osmotic stress
    term:
      id: GO:0071470
      label: cellular response to osmotic stress
  chemical_entities:
  - preferred_term: ammonia
    term:
      id: CHEBI:16134
      label: ammonia
    modifier: INCREASED
  - preferred_term: glutamine
    term:
      id: CHEBI:28300
      label: glutamine
    modifier: INCREASED
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
    explanation: GeneReviews entry describes the cascade from ammonia and glutamine accumulation to cerebral edema and neurological decline.
  downstream:
  - target: Cerebral edema
    description: Glutamine-driven osmotic injury manifests as increased intracranial pressure and cerebral edema.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Astrocyte glutamine accumulation increases intracellular osmolarity and swelling.
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
      explanation: Increased ICP is the clinical marker in this GeneReviews statement for the cerebral edema branch.
  - target: Glutamine
    description: Astrocytic ammonia detoxification during hyperammonemic crises produces glutamine accumulation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Ammonia is incorporated into glutamine by astrocyte glutamine synthetase.
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
      explanation: GeneReviews identifies glutamine as an accumulating toxic metabolite in the hyperammonemic neurologic cascade.
  - target: Encephalopathy
    description: CNS ammonia/glutamine toxicity produces acute hyperammonemic encephalopathy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Shortly thereafter, they develop hyperammonemia and become progressively lethargic, feed poorly, often vomit, and may develop signs of increased intracranial pressure (ICP).
      explanation: GeneReviews describes the clinical encephalopathy sequence after neonatal hyperammonemia develops.
  - target: Lethargy
    description: Early hyperammonemic encephalopathy manifests as progressive lethargy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "become progressively lethargic, feed poorly"
      explanation: GeneReviews directly lists progressive lethargy during neonatal hyperammonemic decompensation.
  - target: Poor feeding
    description: Acute hyperammonemic encephalopathy causes poor feeding in neonatal crises.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "become progressively lethargic, feed poorly"
      explanation: GeneReviews directly lists poor feeding during neonatal hyperammonemic decompensation.
  - target: Vomiting
    description: Vomiting occurs as part of the neonatal hyperammonemic encephalopathy syndrome.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "often vomit"
      explanation: GeneReviews directly lists vomiting during neonatal hyperammonemic decompensation.
  - target: Seizures
    description: Severe hyperammonemic CNS injury can produce seizures.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
      explanation: GeneReviews lists seizures in the hyperammonemic neurologic crisis cascade.
  - target: Coma
    description: Untreated hyperammonemic encephalopathy can progress to loss of consciousness and coma.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
      explanation: Loss of consciousness supports the coma branch of the crisis cascade.
  - target: Spasticity
    description: Increased neuromuscular tone and spasticity occur in severe hyperammonemic crises.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
      explanation: GeneReviews lists increased neuromuscular tone and spasticity in the crisis cascade.
  - target: Intellectual disability
    description: Promptly treated severe neonatal disease may still leave significant neurologic deficits.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Children with the severe form who are treated promptly may survive for an indeterminate period of time, but usually with significant neurologic deficits.
      explanation: GeneReviews supports persistent neurologic deficits after severe hyperammonemic disease.
  - target: Global developmental delay
    description: Severe neonatal hyperammonemic injury can leave developmental and neurologic deficits in survivors.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Children with the severe form who are treated promptly may survive for an indeterminate period of time, but usually with significant neurologic deficits.
      explanation: GeneReviews supports developmental neurologic sequelae in survivors of severe CTLN1.
- name: Genotype-to-phenotype correlation through residual ASS1 activity
  description: 'The severity spectrum of CTLN1 (classic neonatal, late-onset, pregnancy-triggered, asymptomatic) is determined by residual ASS1 enzyme activity. Pathogenic variants affect the citrulline-binding site, oligomerization helix stability, protein expression levels, or cause premature truncation. Variants with less than 2% of wild-type activity typically produce classic neonatal presentations, while hypomorphic variants may allow milder or late-onset disease.

    '
  biological_processes:
  - preferred_term: protein tetramerization
    term:
      id: GO:0051262
      label: protein tetramerization
  genes:
  - preferred_term: ASS1
    term:
      id: hgnc:758
      label: ASS1
  molecular_functions:
  - preferred_term: argininosuccinate synthase activity
    term:
      id: GO:0004055
      label: argininosuccinate synthase activity
  evidence:
  - reference: PMID:39649700
    reference_title: "Visualization of argininosuccinate synthetase by in silico analysis: novel insights into citrullinemia type I disorders."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: the C- terminal helix domain of the mutant protein structure, which was an important structure for ASS1 protein to form protein tetramers, was indeed more unstable than that of the wild-type protein structure.
    explanation: In silico analysis showing C-terminal helix instability disrupts ASS1 tetramerization.
  - reference: PMID:38927689
    reference_title: "Rare Pathogenic Variants in Pooled Whole-Exome Sequencing Data Suggest Hyperammonemia as a Possible Cause of Dementia Not Classified as Alzheimer's Disease or Frontotemporal Dementia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The p.Arg265Cys variant leads to enzyme deficiency, whereas p.Gly390Arg renders the enzyme inactive.
    explanation: Demonstrates that different ASS1 variants produce different degrees of enzyme impairment.
  downstream:
  - target: Impaired hepatic ureagenesis due to ASS1 deficiency
    description: Residual enzyme activity determines the depth of the urea-cycle flux defect.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Variant-specific effects on ASS1 stability, expression, and catalytic activity.
    evidence:
    - reference: PMID:38927689
      reference_title: "Rare Pathogenic Variants in Pooled Whole-Exome Sequencing Data Suggest Hyperammonemia as a Possible Cause of Dementia Not Classified as Alzheimer's Disease or Frontotemporal Dementia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The p.Arg265Cys variant leads to enzyme deficiency, whereas p.Gly390Arg renders the enzyme inactive.
      explanation: Variant-specific differences in residual enzyme activity support variable depth of impaired ureagenesis.
  - target: Secondary metabolic derangements during catabolic stress
    description: Residual ASS1 activity sets crisis threshold under catabolic nitrogen load.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Lower residual ASS1 activity narrows the margin for detoxifying catabolic nitrogen load.
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: emerging evidence suggests that measurement of residual argininosuccinate synthase enzyme activity may help to predict those who are likely to have a severe phenotype and those who are likely to have an attenuated phenotype.
      explanation: GeneReviews links residual ASS1 activity with severity, supporting crisis threshold variation.
- name: Secondary metabolic derangements during catabolic stress
  description: 'Although baseline ureagenesis is impaired, acute hyperammonemic crises are precipitated when nitrogen production exceeds residual detoxification capacity during illness or catabolism. This produces abrupt rises in ammonia and citrulline, orotic aciduria from secondary pyrimidine pathway perturbation, and depleted arginine.

    '
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
  - preferred_term: pyrimidine nucleotide biosynthetic process
    term:
      id: GO:0006221
      label: pyrimidine nucleotide biosynthetic process
  chemical_entities:
  - preferred_term: orotic acid
    term:
      id: CHEBI:16742
      label: orotic acid
    modifier: INCREASED
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Agents/circumstances to avoid: Excessive protein intake, prolonged fasting, and obvious exposure to communicable diseases."
    explanation: GeneReviews identifies excess protein, fasting, and infectious exposure as avoidable triggers for metabolic decompensation.
  downstream:
  - target: Hyperammonemia
    description: Catabolic nitrogen load can exceed residual ASS1-dependent ureagenesis and trigger hyperammonemia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Increased proteolysis and nitrogen production during fasting or illness.
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Agents/circumstances to avoid: Excessive protein intake, prolonged fasting, and obvious exposure to communicable diseases."
      explanation: These avoided circumstances increase metabolic decompensation risk and support a trigger edge to hyperammonemia.
  - target: Orotic acid
    description: During metabolic crises, secondary perturbation of ornithine transcarbamylase/carbamoyl phosphate handling can produce detectable urinary orotic acid.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Poor ornithine bioavailability can impair ornithine transcarbamylase and divert carbamoyl phosphate into pyrimidine intermediates.
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK1458/?report=printable'
      reference_title: "Citrullinemia Type I - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Possibly normal urine organic analysis, although orotic acid may be detected as part of urinary organic acid analysis by gas chromatography/mass spectrometry, especially during metabolic crises.
      explanation: Full GeneReviews diagnostic text supports orotic acid as a crisis-associated urinary organic acid readout in CTLN1.
  - target: Failure to thrive
    description: Recurrent crises and chronic dietary restriction can impair growth, with transplant-associated metabolic stability improving growth outcomes.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:38054409
      reference_title: "Severity-adjusted evaluation of liver transplantation on health outcomes in urea cycle disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: LTx enabled metabolic stability by prevention of further hyperammonemic events after transplantation and was associated with a more favorable growth outcome compared with individuals remaining under MM.
      explanation: Growth improvement after preventing further hyperammonemic events supports the growth branch downstream of recurrent metabolic stress.
phenotypes:
- name: Hyperammonemia
  frequency: VERY_FREQUENT
  description: 'Markedly elevated plasma ammonia is the hallmark biochemical abnormality during metabolic decompensation. In severe neonatal-onset disease, ammonia can exceed 500-1000 umol/L. The median ammonia at diagnosis in deceased UCD patients was 1058 umol/L versus 294 umol/L in survivors.

    '
  phenotype_term:
    preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: PMID:39649700
    reference_title: "Visualization of argininosuccinate synthetase by in silico analysis: novel insights into citrullinemia type I disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'the patient exhibited significantly elevated blood ammonia levels (655 μmol/L; normal reference: 10-30 μmol/L)'
    explanation: Case report with quantitative ammonia data demonstrating severe hyperammonemia in CTLN1.
  - reference: PMID:40218931
    reference_title: "Understanding the Natural History and the Effects of Current Therapeutic Strategies on Urea Cycle Disorders: Insights from the UCD Spanish Registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The median ammonia level in deceased patients was higher at 1058 µmol/L (IQR 410-1793) than in survivors at 294 µmol/L (IQR 71-494)
    explanation: Registry data on ammonia as a prognostic marker in UCD patients.
  sequelae:
  - target: Encephalopathy
    description: Severe hyperammonemia initiates acute neurologic deterioration.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Shortly thereafter, they develop hyperammonemia and become progressively lethargic, feed poorly, often vomit, and may develop signs of increased intracranial pressure (ICP).
      explanation: GeneReviews describes neurologic deterioration after hyperammonemia develops.
  - target: Cerebral edema
    description: Hyperammonemia with glutamine accumulation produces increased intracranial pressure.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Astrocyte glutamine accumulation and osmotic swelling.
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
      explanation: GeneReviews links hyperammonemia and glutamine accumulation to increased ICP.
  - target: Respiratory alkalosis
    description: Acute hyperammonemia can present with tachypnea and respiratory alkalosis during neonatal metabolic decompensation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Ammonia-associated central respiratory stimulation causes tachypnea and hypocapnia.
    evidence:
    - reference: PMID:33113778
      reference_title: "Irritability, Poor Feeding and Respiratory Alkalosis in Newborns: Think about Metabolic Emergencies. A Brief Summary of Hyperammonemia Management."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Their first gas analysis revealed respiratory alkalosis. Hyperammonemia was confirmed, and three different enzymatic blocks in the urea cycle were diagnosed.
      explanation: Newborn UCD case-series evidence links hyperammonemia to respiratory alkalosis during metabolic emergency presentation.
- name: Encephalopathy
  frequency: VERY_FREQUENT
  description: 'Acute or recurrent encephalopathy due to ammonia neurotoxicity, manifesting as progressive lethargy, poor feeding, vomiting, and signs of increased intracranial pressure in neonatal-onset disease.

    '
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
    explanation: GeneReviews describes hyperammonemic encephalopathy progression from lethargy to coma and death.
  sequelae:
  - target: Lethargy
    description: Early encephalopathy manifests as progressive lethargy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Shortly thereafter, they develop hyperammonemia and become progressively lethargic, feed poorly, often vomit, and may develop signs of increased intracranial pressure (ICP).
      explanation: GeneReviews directly lists progressive lethargy during neonatal decompensation.
  - target: Poor feeding
    description: Encephalopathic deterioration causes poor feeding in neonatal crises.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Shortly thereafter, they develop hyperammonemia and become progressively lethargic, feed poorly, often vomit, and may develop signs of increased intracranial pressure (ICP).
      explanation: GeneReviews directly lists poor feeding during neonatal decompensation.
  - target: Vomiting
    description: Vomiting occurs as part of the acute decompensation syndrome.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Shortly thereafter, they develop hyperammonemia and become progressively lethargic, feed poorly, often vomit, and may develop signs of increased intracranial pressure (ICP).
      explanation: GeneReviews directly lists vomiting during neonatal decompensation.
  - target: Seizures
    description: Severe encephalopathy can progress to seizures.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
      explanation: GeneReviews places seizures in the acute neurologic crisis sequence.
  - target: Spasticity
    description: Severe encephalopathy includes increased neuromuscular tone and spasticity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
      explanation: GeneReviews places spasticity in the acute neurologic crisis sequence.
  - target: Coma
    description: Progressive encephalopathy can culminate in loss of consciousness or coma.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
      explanation: Loss of consciousness supports the coma endpoint in severe crises.
- name: Seizures
  frequency: FREQUENT
  description: 'Seizures occur during hyperammonemic crises as part of the encephalopathic cascade, reflecting cerebral edema and neuronal dysfunction.

    '
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:39649700
    reference_title: "Visualization of argininosuccinate synthetase by in silico analysis: novel insights into citrullinemia type I disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The patient was characterized by severe clinical manifestations, including poor responsiveness, lethargy, convulsions, and cardiac arrest.
    explanation: Case report documenting convulsions as part of severe neonatal CTLN1 presentation.
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
    explanation: GeneReviews confirms seizures as a manifestation of hyperammonemic encephalopathy.
- name: Lethargy
  frequency: VERY_FREQUENT
  description: 'Progressive lethargy is one of the earliest signs of hyperammonemic decompensation in neonatal-onset CTLN1, often progressing to coma.

    '
  phenotype_term:
    preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  evidence:
  - reference: PMID:39649700
    reference_title: "Visualization of argininosuccinate synthetase by in silico analysis: novel insights into citrullinemia type I disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The patient was characterized by severe clinical manifestations, including poor responsiveness, lethargy, convulsions, and cardiac arrest.
    explanation: Case report documenting lethargy as a presenting feature of severe neonatal CTLN1.
- name: Poor feeding
  frequency: VERY_FREQUENT
  description: 'Feeding difficulties and refusal are common early signs in neonatal-onset CTLN1, reflecting encephalopathic progression.

    '
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Shortly thereafter, they develop hyperammonemia and become progressively lethargic, feed poorly, often vomit, and may develop signs of increased intracranial pressure (ICP).
    explanation: GeneReviews directly describes poor feeding in neonatal CTLN1.
- name: Vomiting
  frequency: FREQUENT
  description: 'Recurrent vomiting occurs during metabolic decompensation episodes.

    '
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Shortly thereafter, they develop hyperammonemia and become progressively lethargic, feed poorly, often vomit, and may develop signs of increased intracranial pressure (ICP).
    explanation: GeneReviews directly lists vomiting in neonatal CTLN1 decompensation.
- name: Intellectual disability
  frequency: FREQUENT
  description: 'Intellectual disability results from cumulative or irreversible early brain injury during hyperammonemic episodes. Neurological impairment occurred in 44% of patients in the Spanish UCD registry. Neurocognitive outcomes did not improve even after liver transplantation, suggesting early irreversible injury.

    '
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:40218931
    reference_title: "Understanding the Natural History and the Effects of Current Therapeutic Strategies on Urea Cycle Disorders: Insights from the UCD Spanish Registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Neurological impairment occurred in 44% of patients, with worse neurological outcomes observed in patients with argininosuccinate lyase deficiency, arginase 1 deficiency, hyperornithinemia-hyperammonemia-homocitrullinuria, EO presentations, pre-2014 diagnosis, and patients with higher levels of ammonia at diagnosis.
    explanation: Registry data showing neurological impairment in 44% of UCD patients.
- name: Global developmental delay
  frequency: FREQUENT
  description: 'Developmental delay is common in survivors of neonatal-onset CTLN1, particularly those with early hyperammonemic events.

    '
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:40218931
    reference_title: "Understanding the Natural History and the Effects of Current Therapeutic Strategies on Urea Cycle Disorders: Insights from the UCD Spanish Registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Neurological impairment occurred in 44% of patients
    explanation: High rate of neurological impairment in UCD patients supports developmental delay as a common outcome.
- name: Cerebral edema
  frequency: FREQUENT
  description: 'Cerebral edema develops during severe hyperammonemic crises through astrocyte glutamine-mediated osmotic swelling, manifesting as increased intracranial pressure.

    '
  phenotype_term:
    preferred_term: Cerebral edema
    term:
      id: HP:0002181
      label: Cerebral edema
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
    explanation: GeneReviews describes increased ICP (intracranial pressure) as a direct consequence of hyperammonemia.
- name: Spasticity
  frequency: OCCASIONAL
  description: 'Increased neuromuscular tone and spasticity can develop as part of hyperammonemic encephalopathy and chronic neurological sequelae.

    '
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
    explanation: GeneReviews lists spasticity among the neurological manifestations of hyperammonemic crises.
- name: Coma
  frequency: OCCASIONAL
  description: 'Coma develops in untreated or refractory hyperammonemic crises and is associated with high mortality if not urgently managed.

    '
  phenotype_term:
    preferred_term: Coma
    term:
      id: HP:0001259
      label: Coma
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
    explanation: Loss of consciousness progressing to coma is described as part of the hyperammonemic crisis cascade.
- name: Failure to thrive
  frequency: FREQUENT
  description: 'Poor growth due to chronic protein restriction, recurrent metabolic crises, and catabolic episodes.

    '
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:38054409
    reference_title: "Severity-adjusted evaluation of liver transplantation on health outcomes in urea cycle disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: LTx enabled metabolic stability by prevention of further hyperammonemic events after transplantation and was associated with a more favorable growth outcome compared with individuals remaining under MM.
    explanation: Growth improvement after liver transplant implies growth impairment during medical management.
- name: Respiratory alkalosis
  frequency: OCCASIONAL
  description: 'Respiratory alkalosis may occur during hyperammonemic crises due to central stimulation of respiration by ammonia.

    '
  phenotype_term:
    preferred_term: Respiratory alkalosis
    term:
      id: HP:0001950
      label: Respiratory alkalosis
  evidence:
  - reference: PMID:33113778
    reference_title: "Irritability, Poor Feeding and Respiratory Alkalosis in Newborns: Think about Metabolic Emergencies. A Brief Summary of Hyperammonemia Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This report aims to highlight the importance of suspecting urea cycle disorders in newborns with aspecific signs of hyperammonemia and respiratory alkalosis
    explanation: Human newborn UCD cases support respiratory alkalosis as a hyperammonemic crisis feature relevant to CTLN1.
biochemical:
- name: Citrulline
  presence: INCREASED
  context: 'Markedly elevated plasma citrulline is the defining biochemical hallmark of CTLN1. In classic disease, citrulline can reach 2000-5000 umol/L (normal less than 60 umol/L). This is the primary marker on newborn screening.

    '
  readouts:
  - target: Impaired hepatic ureagenesis due to ASS1 deficiency
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Markedly elevated citrulline reports the blocked ASS1 step upstream of argininosuccinate formation.
  biomarker_term:
    preferred_term: citrulline
    term:
      id: CHEBI:18211
      label: citrulline
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: elevated plasma citrulline concentration (usually >500 µmol/L)
    explanation: GeneReviews gives elevated plasma citrulline as a diagnostic biochemical feature of CTLN1.
  - reference: PMID:39649700
    reference_title: "Visualization of argininosuccinate synthetase by in silico analysis: novel insights into citrullinemia type I disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'increased citrulline concentrations (936 μmol/L; normal reference: 5-25 μmol/L)'
    explanation: Quantitative case data support markedly increased citrulline.
- name: Ammonia
  presence: INCREASED
  context: 'Elevated blood ammonia results from impaired ureagenesis. During acute crises, ammonia can exceed 500-1000 umol/L. Diagnostic ammonia levels are a key prognostic marker; deceased UCD patients had median ammonia of 1058 umol/L versus 294 umol/L in survivors.

    '
  readouts:
  - target: Impaired hepatic ureagenesis due to ASS1 deficiency
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated ammonia reports failed hepatic nitrogen disposal through the urea cycle.
  biomarker_term:
    preferred_term: ammonia
    term:
      id: CHEBI:16134
      label: ammonia
  evidence:
  - reference: PMID:39649700
    reference_title: "Visualization of argininosuccinate synthetase by in silico analysis: novel insights into citrullinemia type I disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: 'the patient exhibited significantly elevated blood ammonia levels (655 μmol/L; normal reference: 10-30 μmol/L)'
    explanation: Quantitative demonstration of severe hyperammonemia in a CTLN1 case.
  - reference: PMID:40218931
    reference_title: "Understanding the Natural History and the Effects of Current Therapeutic Strategies on Urea Cycle Disorders: Insights from the UCD Spanish Registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The median ammonia level in deceased patients was higher at 1058 µmol/L (IQR 410-1793) than in survivors at 294 µmol/L (IQR 71-494)
    explanation: Registry data establishing ammonia as a prognostic marker.
- name: Arginine
  presence: DECREASED
  context: 'Low plasma arginine is a secondary biochemical feature reflecting the inability to synthesize argininosuccinate, the immediate precursor of arginine via argininosuccinate lyase. Arginine supplementation is part of standard management.

    '
  readouts:
  - target: Impaired hepatic ureagenesis due to ASS1 deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Low-to-normal arginine is interpreted together with elevated citrulline and absent argininosuccinate as part of the ASS1-block biochemical pattern.
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK1458/?report=printable'
      reference_title: "Citrullinemia Type I - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Plasma amino acids analysis demonstrating elevated citrulline, absent argininosuccinate, with low-to-normal arginine and ornithine levels
      explanation: Full GeneReviews diagnostic text supports low-to-normal arginine as a biochemical readout of the ASS1 urea-cycle block.
  biomarker_term:
    preferred_term: L-arginine
    term:
      id: CHEBI:16467
      label: L-arginine
  evidence:
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK1458/?report=printable'
    reference_title: "Citrullinemia Type I - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Plasma amino acids analysis demonstrating elevated citrulline, absent argininosuccinate, with low-to-normal arginine and ornithine levels
    explanation: Full GeneReviews diagnostic text directly supports low-to-normal plasma arginine in CTLN1.
- name: Argininosuccinate
  presence: DECREASED
  context: 'Absent or markedly reduced argininosuccinate is the immediate biochemical consequence of the ASS1 block, since argininosuccinate synthase normally condenses citrulline and aspartate to form argininosuccinate.

    '
  readouts:
  - target: Impaired hepatic ureagenesis due to ASS1 deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Absent argininosuccinate directly reports failure of ASS1-mediated citrulline-aspartate condensation.
  biomarker_term:
    preferred_term: argininosuccinate
    term:
      id: CHEBI:15682
      label: (N(omega)-L-arginino)succinic acid
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: elevated plasma ammonia concentration (>150 µmol/L; may range to ≥2000-3000 µmol/L), elevated plasma citrulline concentration (usually >500 µmol/L), and absent argininosuccinate
    explanation: GeneReviews lists absent argininosuccinate as part of the diagnostic biochemical pattern of CTLN1.
- name: Orotic acid
  presence: INCREASED
  context: 'Elevated urinary orotic acid (orotic aciduria) is a secondary marker reflecting accumulation of carbamoyl phosphate that is diverted into the pyrimidine synthesis pathway when ureagenesis is blocked.

    '
  readouts:
  - target: Secondary metabolic derangements during catabolic stress
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Detectable urinary orotic acid during crises reports secondary pyrimidine-pathway diversion in the decompensated urea-cycle state.
    evidence:
    - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK1458/?report=printable'
      reference_title: "Citrullinemia Type I - GeneReviews® - NCBI Bookshelf"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Possibly normal urine organic analysis, although orotic acid may be detected as part of urinary organic acid analysis by gas chromatography/mass spectrometry, especially during metabolic crises.
      explanation: Full GeneReviews diagnostic text supports urinary orotic acid as a crisis-associated readout.
  biomarker_term:
    preferred_term: orotic acid
    term:
      id: CHEBI:16742
      label: orotic acid
  evidence:
  - reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK1458/?report=printable'
    reference_title: "Citrullinemia Type I - GeneReviews® - NCBI Bookshelf"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Possibly normal urine organic analysis, although orotic acid may be detected as part of urinary organic acid analysis by gas chromatography/mass spectrometry, especially during metabolic crises.
    explanation: Full GeneReviews diagnostic text directly supports orotic acid detection in CTLN1, especially during metabolic crises.
- name: Glutamine
  presence: INCREASED
  context: 'Elevated plasma and brain glutamine reflects astrocytic ammonia detoxification. Glutamine accumulation in astrocytes is the direct driver of osmotic swelling and cerebral edema during hyperammonemic crises.

    '
  readouts:
  - target: Hyperammonemic neurotoxicity via astrocyte glutamine-osmotic injury
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated glutamine reports ammonia detoxification and the osmotic neurotoxicity branch during hyperammonemic crises.
  biomarker_term:
    preferred_term: glutamine
    term:
      id: CHEBI:28300
      label: glutamine
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
    explanation: GeneReviews identifies glutamine as a toxic metabolite that accumulates in CTLN1.
genetic:
- name: ASS1 pathogenic variants
  gene_term:
    preferred_term: ASS1
    term:
      id: hgnc:758
      label: ASS1
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:37485339
      reference_title: "Functional identification of two novel variants and a hypomorphic variant in ASS1 from patients with Citrullinemia type I."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Citrullinemia type I (CTLN1) is a rare autosomal recessive inborn error of the urea cycle caused by mutations in the gene encoding the arginosuccinate synthetase (ASS1) enzyme.
      explanation: Directly states autosomal recessive inheritance for CTLN1.
  variants:
  - name: ASS1 - p.P217del (c.649-651del)
    description: 'Novel in-frame deletion that results in decreased ASS1 expression at both protein and transcription levels, with highly significant reduction in enzyme activity.

      '
  - name: ASS1 - p.Q350* (c.1048C>T)
    description: 'Novel nonsense variant producing a truncated ASS1 protein with marked decrease in expression at the protein level and highly significant reduction in enzyme activity.

      '
    evidence:
    - reference: PMID:37485339
      reference_title: "Functional identification of two novel variants and a hypomorphic variant in ASS1 from patients with Citrullinemia type I."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The other novel variant, c.1048C>T (p.Q350*), showed a marked decrease in expression at the protein level, with the formation of truncated proteins but an increased transcription.
      explanation: Functional characterization of a novel truncating ASS1 variant.
  - name: ASS1 - p.Arg265Cys (rs148918985)
    description: 'Rare pathogenic coding variant leading to ASS1 enzyme deficiency. Found in patients with late-onset citrullinemia type I and associated with hyperammonemia-related dementia.

      '
    evidence:
    - reference: PMID:38927689
      reference_title: "Rare Pathogenic Variants in Pooled Whole-Exome Sequencing Data Suggest Hyperammonemia as a Possible Cause of Dementia Not Classified as Alzheimer's Disease or Frontotemporal Dementia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The p.Arg265Cys variant leads to enzyme deficiency, whereas p.Gly390Arg renders the enzyme inactive.
      explanation: Demonstrates that p.Arg265Cys causes partial enzyme deficiency consistent with late-onset disease.
  - name: ASS1 - p.Gly390Arg (rs121908641)
    description: 'Rare pathogenic coding variant that renders ASS1 enzyme completely inactive. In compound heterozygosity can produce late-onset citrullinemia type I.

      '
    evidence:
    - reference: PMID:38927689
      reference_title: "Rare Pathogenic Variants in Pooled Whole-Exome Sequencing Data Suggest Hyperammonemia as a Possible Cause of Dementia Not Classified as Alzheimer's Disease or Frontotemporal Dementia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The p.Arg265Cys variant leads to enzyme deficiency, whereas p.Gly390Arg renders the enzyme inactive.
      explanation: Demonstrates that p.Gly390Arg abolishes enzyme activity.
  - name: ASS1 - c.-4C>T (5'UTR hypomorphic variant)
    description: 'A non-coding variant in the 5''UTR region of ASS1 that reduces expression at both protein and transcription levels but does not directly affect enzyme activity. Represents a hypomorphic variant that may modify disease severity.

      '
  features: 'Over 100 pathogenic variants in ASS1 have been documented. The clinical spectrum from classic neonatal-onset to asymptomatic is determined by residual enzyme activity. Variants affecting the citrulline-binding site, the C-terminal oligomerization helix required for tetramer formation, or causing premature truncation typically produce severe disease, while hypomorphic variants allow milder presentations. Nonsense mutations account for approximately 7-10% of ASS1 variants.

    '
  evidence:
  - reference: PMID:39649700
    reference_title: "Visualization of argininosuccinate synthetase by in silico analysis: novel insights into citrullinemia type I disorders."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: the C- terminal helix domain of the mutant protein structure, which was an important structure for ASS1 protein to form protein tetramers, was indeed more unstable than that of the wild-type protein structure.
    explanation: Structural analysis demonstrating how specific variants disrupt ASS1 tetramer stability.
  - reference: PMID:37485339
    reference_title: "Functional identification of two novel variants and a hypomorphic variant in ASS1 from patients with Citrullinemia type I."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Both c.649_651del (p.P217del) and c.1048C>T (p.Q350*) showed a highly significant reduction in enzyme activity, while c.-4C>T had no effect.
    explanation: Functional studies demonstrating variable residual activity across different ASS1 variant types.
  - reference: PMID:39449289
    reference_title: "Exploring RNA therapeutics for urea cycle disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: LNP-formulated mRNA therapy has been assayed preclinically for citrullinemia type I (CTLN1), adolescent and adult citrin deficiency, argininosuccinic aciduria, arginase deficiency and ornithine transcarbamylase deficiency
    explanation: Review noting nonsense mutations in approximately 7-10% of ASS1, relevant for therapeutic targeting.
  - reference: CGGV:assertion_5dc5ef32-81ca-478e-be42-436da3416e4d-2018-12-27T170000.000Z
    reference_title: "ASS1 / citrullinemia type I (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ASS1 | HGNC:758 | citrullinemia type I | MONDO:0008988 | AR | Definitive"
    explanation: ClinGen classifies the ASS1-citrullinemia type I gene-disease relationship as definitive with autosomal recessive inheritance.
treatments:
- name: Protein-restricted diet with essential amino acid supplementation
  description: 'Long-term dietary management centers on restriction of protein intake to reduce nitrogen load while providing essential amino acids via specialized formula. This is the cornerstone of chronic CTLN1 management. Liver transplantation eliminates the need for protein restriction.

    '
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:38054409
    reference_title: "Severity-adjusted evaluation of liver transplantation on health outcomes in urea cycle disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: LTx enabled metabolic stability without further need of protein restriction or nitrogen-scavenging therapy
    explanation: Confirms that protein restriction is standard pre-transplant medical management for UCDs.
  target_mechanisms:
  - target: Secondary metabolic derangements during catabolic stress
    treatment_effect: INHIBITS
    description: Protein restriction lowers exogenous nitrogen load and reduces the risk that residual ureagenesis will be overwhelmed.
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Daily routine treatment in those who have not undergone a liver transplantation includes lifelong protein restriction in conjunction with a metabolic nutritionist; nitrogen scavenger medications; arginine supplementation;
      explanation: GeneReviews identifies lifelong protein restriction as a routine treatment used to prevent metabolic decompensation.
- name: Nitrogen scavenger therapy
  description: 'Sodium benzoate, sodium phenylbutyrate, or glycerol phenylbutyrate are used to promote alternative nitrogen disposal pathways. These agents conjugate with glycine or glutamine to form hippurate or phenylacetylglutamine, which are renally excreted, thus bypassing the blocked urea cycle.

    '
  treatment_term:
    preferred_term: nitrogen scavenger therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sodium benzoate
      term:
        id: CHEBI:113455
        label: sodium benzoate
    - preferred_term: sodium phenylbutyrate
      term:
        id: CHEBI:75316
        label: sodium phenylbutyrate
    - preferred_term: glycerol phenylbutyrate
      term:
        id: CHEBI:134745
        label: glycerol phenylbutyrate
  evidence:
  - reference: PMID:38054409
    reference_title: "Severity-adjusted evaluation of liver transplantation on health outcomes in urea cycle disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: LTx enabled metabolic stability without further need of protein restriction or nitrogen-scavenging therapy
    explanation: Confirms nitrogen scavenger therapy as part of standard medical management for UCDs prior to transplant.
  - reference: PMID:27860485
    reference_title: "An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Ammonia-scavenging drugs, benzoate and phenylacetate (PA)/phenylbutyrate (PB), modulate hepatic nitrogen metabolism mainly by providing alternative pathways for nitrogen disposal.
    explanation: Review evidence defines the nitrogen-scavenger mechanism as alternative nitrogen disposal.
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  target_mechanisms:
  - target: Impaired hepatic ureagenesis due to ASS1 deficiency
    treatment_effect: BYPASSES
    description: Scavenger drugs bypass the compromised urea cycle by providing alternative nitrogen-disposal routes.
    evidence:
    - reference: PMID:27860485
      reference_title: "An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Ammonia-scavenging drugs, benzoate and phenylacetate (PA)/phenylbutyrate (PB), modulate hepatic nitrogen metabolism mainly by providing alternative pathways for nitrogen disposal.
      explanation: The review directly supports a bypass edge from scavenger therapy around the blocked urea cycle through alternative nitrogen disposal.
- name: Arginine supplementation
  description: 'Arginine supplementation is required because the ASS1 block prevents endogenous arginine synthesis. Supplemental arginine also helps drive residual urea cycle flux and supports protein synthesis.

    '
  treatment_term:
    preferred_term: nutritional supplementation
    term:
      id: MAXO:0000106
      label: nutritional supplementation
    therapeutic_agent:
    - preferred_term: L-arginine
      term:
        id: CHEBI:16467
        label: L-arginine
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Daily routine treatment in those who have not undergone a liver transplantation includes lifelong protein restriction in conjunction with a metabolic nutritionist; nitrogen scavenger medications; arginine supplementation;
    explanation: GeneReviews directly states arginine supplementation is part of standard CTLN1 management.
  - reference: PMID:10869432
    reference_title: "In vivo urea cycle flux distinguishes and correlates with phenotypic severity in disorders of the urea cycle."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Administration of Ucephan lowered, and arginine increased, urea synthesis to the degree predicted from their respective rates of metabolism.
    explanation: Stable-isotope human data support arginine supplementation as a modifier of urea synthesis in urea-cycle patients.
  target_mechanisms:
  - target: Impaired hepatic ureagenesis due to ASS1 deficiency
    treatment_effect: MODULATES
    description: Arginine supplementation provides the downstream urea-cycle amino acid and increases measured urea synthesis in vivo.
    evidence:
    - reference: PMID:10869432
      reference_title: "In vivo urea cycle flux distinguishes and correlates with phenotypic severity in disorders of the urea cycle."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Urea synthesis is altered by alternative route medications and arginine supplementation to the degree that is to be expected from theory.
      explanation: Human isotope-flux data support a mechanism link from arginine supplementation to altered urea-cycle flux.
- name: Acute crisis management
  description: 'Emergency management of hyperammonemic crises includes cessation of protein intake (maximum 48 hours), high-calorie glucose infusion to reverse catabolism, intravenous nitrogen scavengers, and escalation to continuous renal replacement therapy (dialysis) when ammonia exceeds 500 umol/L.

    '
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Without prompt intervention, hyperammonemia and the accumulation of other toxic metabolites (e.g., glutamine) result in increased ICP, increased neuromuscular tone, spasticity, ankle clonus, seizures, loss of consciousness, and death.
    explanation: GeneReviews emphasizes the need for prompt intervention during hyperammonemic crises.
  - reference: PMID:40218931
    reference_title: "Understanding the Natural History and the Effects of Current Therapeutic Strategies on Urea Cycle Disorders: Insights from the UCD Spanish Registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: EO cases presented a higher mortality rate (35.8%) than late-onset (LO) cases (7.1%)
    explanation: High mortality in early-onset cases underscores the importance of acute crisis management.
  target_mechanisms:
  - target: Hyperammonemic neurotoxicity via astrocyte glutamine-osmotic injury
    treatment_effect: INHIBITS
    description: Acute crisis therapy rapidly lowers ammonia and reverses catabolism to prevent the CNS glutamine-osmotic injury cascade.
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Acute inpatient treatment of a metabolic crisis includes addressing hyperammonemia through withholding of all protein intake for a maximum of 24 to 28 hours; pharmacologic nitrogen scavenger therapy; and consideration of dialysis
      explanation: GeneReviews directly links acute crisis therapy to rapid hyperammonemia management.
- name: Liver transplantation
  description: 'Liver transplantation is the only established curative intervention at the metabolic level for CTLN1. It provides metabolic stability by restoring hepatic ASS1 activity, preventing further hyperammonemic events, and allowing liberalization of protein intake. Five-year patient survival exceeds 90%. However, pre-existing neurocognitive impairment does not improve after transplantation.

    '
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
  evidence:
  - reference: PMID:38054409
    reference_title: "Severity-adjusted evaluation of liver transplantation on health outcomes in urea cycle disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: LTx enabled metabolic stability by prevention of further hyperammonemic events after transplantation and was associated with a more favorable growth outcome compared with individuals remaining under MM.
    explanation: Severity-adjusted analysis demonstrating metabolic stability and growth benefit after liver transplant in UCDs.
  - reference: PMID:40218931
    reference_title: "Understanding the Natural History and the Effects of Current Therapeutic Strategies on Urea Cycle Disorders: Insights from the UCD Spanish Registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among transplanted patients (20.6%), survival was 95.2%, with no significant neurological differences compared to non-transplanted patients.
    explanation: Registry data showing high transplant survival but persistent neurological challenges.
  target_mechanisms:
  - target: ASS1 molecular function deficiency
    treatment_effect: RESTORES
    description: Liver transplantation replaces the deficient hepatic urea-cycle capacity and prevents further hyperammonemic events.
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Liver transplantation is the only known curative therapy and eliminates the need for dietary restriction.
      explanation: GeneReviews supports transplantation as the metabolic-level corrective intervention for CTLN1.
- name: Newborn screening
  description: 'CTLN1 is detectable by newborn screening via tandem mass spectrometry using elevated citrulline as the primary marker. Early detection enables treatment initiation before clinical decompensation and is associated with improved survival and reduced neurological impairment.

    '
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  evidence:
  - reference: PMID:40218931
    reference_title: "Understanding the Natural History and the Effects of Current Therapeutic Strategies on Urea Cycle Disorders: Insights from the UCD Spanish Registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Diagnosis through NBS improved survival and reduced neurological impairment compared to symptomatic diagnosis.
    explanation: Registry evidence that newborn screening improves outcomes in UCDs.
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  - preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
- name: Genetic counseling
  description: 'Genetic counseling for affected families, including discussion of autosomal recessive inheritance, 25% recurrence risk for carrier parents, prenatal testing options, and carrier testing for at-risk relatives.

    '
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  target_mechanisms:
  - target: ASS1 molecular function deficiency
    treatment_effect: MODULATES
    description: Counseling uses the confirmed ASS1 molecular etiology to address recurrence risk, carrier testing, and prenatal testing rather than directly altering enzyme activity.
    evidence:
    - reference: PMID:20301631
      reference_title: "Citrullinemia Type I."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Carrier testing for at-risk relatives and prenatal testing for a pregnancy at increased risk are possible if the pathogenic variants in the family are known.
      explanation: GeneReviews supports variant-informed genetic counseling for families with CTLN1.
  evidence:
  - reference: PMID:37485339
    reference_title: "Functional identification of two novel variants and a hypomorphic variant in ASS1 from patients with Citrullinemia type I."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Molecular genetic testing is critical for patient diagnosis.
    explanation: Genetic testing is essential for CTLN1, supporting the role of genetic counseling.
- name: Emerging RNA therapeutics
  description: 'LNP-formulated mRNA therapy has been assayed preclinically for CTLN1, representing an emerging disease-modifying strategy for liver-targeted gene correction. This approach could potentially provide metabolic correction without transplantation.

    '
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:39449289
    reference_title: "Exploring RNA therapeutics for urea cycle disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: LNP-formulated mRNA therapy has been assayed preclinically for citrullinemia type I (CTLN1), adolescent and adult citrin deficiency, argininosuccinic aciduria, arginase deficiency and ornithine transcarbamylase deficiency
    explanation: Review documenting preclinical mRNA therapy development specifically for CTLN1.
  target_mechanisms:
  - target: ASS1 molecular function deficiency
    treatment_effect: RESTORES
    description: Liver-targeted ASS1 mRNA replacement would restore the deficient enzyme activity upstream of the urea-cycle block.
    evidence:
    - reference: PMID:39449289
      reference_title: "Exploring RNA therapeutics for urea cycle disorders."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: LNP-formulated mRNA therapy has been assayed preclinically for citrullinemia type I (CTLN1), adolescent and adult citrin deficiency, argininosuccinic aciduria, arginase deficiency and ornithine transcarbamylase deficiency
      explanation: The review identifies preclinical CTLN1 mRNA therapy, supporting a restorative target mechanism.
progression:
- evidence:
  - reference: PMID:40218931
    reference_title: "Understanding the Natural History and the Effects of Current Therapeutic Strategies on Urea Cycle Disorders: Insights from the UCD Spanish Registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: EO cases presented a higher mortality rate (35.8%) than late-onset (LO) cases (7.1%)
    explanation: Registry data quantifying the mortality difference between early and late-onset UCD presentations.
  - reference: PMID:20301631
    reference_title: "Citrullinemia Type I."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Citrullinemia type I (CTLN1) presents as a spectrum that includes a neonatal acute form (the "classic" form), a milder late-onset form (the "non-classic" form), a form in which women have onset of symptoms at pregnancy or post partum, and a form without symptoms or hyperammonemia.
    explanation: GeneReviews describes the full clinical spectrum of CTLN1 presentations.
  notes: 'Classic neonatal-onset CTLN1 presents within the first days of life with progressive lethargy, poor feeding, vomiting, and hyperammonemic encephalopathy that can rapidly progress to coma and death without treatment. Late-onset forms present with intermittent hyperammonemia, developmental delay, and neurocognitive impairment. A pregnancy/postpartum-triggered form can present in women without prior symptoms. Long-term outcomes are determined by severity and number of hyperammonemic events, with early-onset cases having 35.8% mortality versus 7.1% in late-onset cases. Neurological impairment occurs in 44% of UCD patients overall. Liver transplantation can stabilize metabolism but does not reverse pre-existing brain injury.

    '
notes: 'CTLN1 is the second most common urea cycle disorder. The Alshaya et al. 2018 review (DOI:10.1007/s40138-018-0174-5) provides additional detail on the astrocyte glutamine-osmotic injury mechanism but was not indexed in PubMed. The GeneReviews entry (PMID:20301631) serves as a comprehensive clinical reference for classic and non-classic CTLN1 management.

  '
references:
- reference: PMID:20301631
  title: "Citrullinemia Type I."
  tags:
  - GeneReviews
  findings: []
- reference: 'url:https://www.ncbi.nlm.nih.gov/books/NBK1458/?report=printable'
  title: "Citrullinemia Type I - GeneReviews® - NCBI Bookshelf"
  tags:
  - GeneReviews
  findings: []
📚

References & Deep Research

References

2
PMID:20301631
Citrullinemia Type I.
No top-level findings curated for this source.
url:https://www.ncbi.nlm.nih.gov/books/NBK1458/?report=printable
Citrullinemia Type I - GeneReviews® - NCBI Bookshelf
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Pathophysiology Research Template
Edison Scientific Literature 27 citations 2026-02-23T23:36:55.196705

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Citrullinemia Type I
  • MONDO ID: (if available)
  • Category: Genetic

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Citrullinemia Type I. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Title: Pathophysiology of Citrullinemia Type I (CTLN1; ASS1 deficiency) — 2023–2024-focused Research Report

  1. Disease identity, definitions, and current understanding

Citrullinemia type I (CTLN1; “argininosuccinate synthetase deficiency”) is an autosomal recessive urea-cycle disorder caused by biallelic pathogenic variants in ASS1 (OMIM #215700). ASS1 encodes argininosuccinate synthase, a cytosolic enzyme of the urea cycle that catalyzes the condensation of citrulline and aspartate to form argininosuccinate (the third enzymatic step of the urea cycle) and is reported to be mainly expressed in periportal hepatocytes. (liu2023functionalidentificationof pages 1-2, gu2024visualizationofargininosuccinate pages 1-2)

Core biochemical hallmarks used clinically to recognize CTLN1 include hyperammonemia, elevated plasma citrulline, low plasma arginine, and increased urinary orotic acid (orotic aciduria), reflecting a functional block in nitrogen disposal and secondary perturbations of pyrimidine metabolism. (liu2023functionalidentificationof pages 1-2, gu2024visualizationofargininosuccinate pages 2-4, gu2024visualizationofargininosuccinate pages 1-2)

MONDO identifier: not confirmed in the retrieved full-text corpus during this run; should be added from MONDO/Ontobee in a subsequent curation step.

  1. Core pathophysiology (molecular and cellular mechanisms)

2.1 Primary biochemical lesion: cytosolic urea-cycle block

ASS1 deficiency disrupts ureagenesis by limiting conversion of citrulline + aspartate → argininosuccinate. This leads to accumulation of upstream substrates (notably citrulline) and failure to detoxify nitrogen, causing hyperammonemia. (liu2023functionalidentificationof pages 1-2, gu2024visualizationofargininosuccinate pages 1-2)

Representative quantitative laboratory abnormalities reported in a 2024 CTLN1 case report include ammonia rising to 655 μmol/L (reference 10–30 μmol/L) and citrulline 936 μmol/L (reference 5–25 μmol/L). (gu2024visualizationofargininosuccinate media 3a7cd48b, gu2024visualizationofargininosuccinate pages 1-2)

A 2024 genetics-focused analysis of urea-cycle gene variants summarized that “classical citrullinemia shows elevated blood citrulline levels 2000–5000 µmol/L (normal < 60)” (context: distinguishing classic from milder forms), emphasizing the magnitude of metabolite accumulation in severe disease. (karachanakyankova2024rarepathogenicvariants pages 5-7)

2.2 Hyperammonemic neurotoxicity: astrocyte glutamine-osmotic injury → cerebral edema

A key mechanistic model for CNS injury in CTLN1 (and other UCDs) is that ammonia that enters the brain is rapidly detoxified by astrocytes via conversion to glutamine. A clinical review of hyperammonemia states that ammonia is “detoxified via conversion to glutamine in astrocytes,” and that “rapid intracellular glutamine accumulation increases osmolarity causing astrocyte swelling… and cerebral edema.” (alshaya2018intravenousandoral pages 1-2)

This mechanism connects systemic metabolic failure (hepatic ureagenesis deficit) to cellular brain pathology (astrocyte swelling and downstream neuronal dysfunction), explaining acute symptoms such as lethargy, seizures, increased intracranial pressure, and coma during hyperammonemic crises. (alshaya2018intravenousandoral pages 1-2, simpson2025ureacycledisorders pages 1-4, karachanakyankova2024rarepathogenicvariants pages 5-7)

2.3 Genotype-to-molecular phenotype: disrupted catalysis or tetramerization reduces residual activity

Recent human genetics/functional work supports a residual-activity model for CTLN1 severity. In a 2024 study analyzing ASS1 variants, two pathogenic missense variants were described as having “below 2% of the wild-type protein enzymatic activity,” and the phenotype spectrum was explicitly linked to residual activity (classic neonatal vs late-onset/pregnancy-triggered vs asymptomatic). (karachanakyankova2024rarepathogenicvariants pages 5-7)

Structural mechanisms implicated include distortion of the citrulline-binding site and disruption of an “oligomerization helix” important for the oligomeric state of ASS1, consistent with other 2024 in silico work emphasizing instability of a C-terminal helix required for tetramer formation. (karachanakyankova2024rarepathogenicvariants pages 5-7, gu2024visualizationofargininosuccinate pages 1-2)

  1. Key molecular players (genes/proteins, metabolites, cells, anatomy)

3.1 Genes/Proteins (HGNC)

• ASS1 (HGNC:758) — argininosuccinate synthase 1; cytosolic enzyme of the urea cycle; deficiency causes CTLN1. (liu2023functionalidentificationof pages 1-2, gu2024visualizationofargininosuccinate pages 1-2)

3.2 Chemical entities / metabolites (ChEBI)

Primary diagnostic/causal metabolites: • Ammonia (NH3/NH4+) — accumulates due to impaired ureagenesis; principal driver of acute neurotoxicity. (alshaya2018intravenousandoral pages 1-2, karachanakyankova2024rarepathogenicvariants pages 5-7) • Citrulline — accumulates upstream of ASS1 block; markedly elevated in plasma in classic disease. (liu2023functionalidentificationof pages 1-2, karachanakyankova2024rarepathogenicvariants pages 5-7)

Key secondary/related metabolites: • Arginine — low plasma arginine reported as a biochemical marker in CTLN1. (liu2023functionalidentificationof pages 1-2, gu2024visualizationofargininosuccinate pages 2-4) • Aspartate — ASS1 substrate; central to the blocked reaction. (liu2023functionalidentificationof pages 1-2) • Glutamine — rises in brain/astrocytes during ammonia detoxification; implicated in osmotic swelling and cerebral edema. (alshaya2018intravenousandoral pages 1-2, karachanakyankova2024rarepathogenicvariants pages 5-7) • Orotic acid — increased urinary excretion (orotic aciduria), reflecting secondary pathway effects. (liu2023functionalidentificationof pages 1-2, gu2024visualizationofargininosuccinate pages 2-4)

Therapy-relevant small molecules (used across UCDs, including CTLN1): • Sodium benzoate; sodium phenylbutyrate; glycerol phenylbutyrate — “nitrogen scavengers” that remove nitrogen through alternative pathways. (yin2024asurvivalguide pages 16-19, posset2024severityadjustedevaluationof pages 1-2)

3.3 Cell types (Cell Ontology, CL)

• Hepatocytes (periportal hepatocytes in particular) — predominant ASS1 expression and site of physiologic ureagenesis. (liu2023functionalidentificationof pages 1-2, gu2024visualizationofargininosuccinate pages 1-2) • Astrocytes — principal brain-resident ammonia-detoxifying cells implicated in glutamine-mediated swelling/edema. (alshaya2018intravenousandoral pages 1-2)

3.4 Anatomical locations (UBERON)

• Liver (periportal region) — primary site of urea cycle flux and ASS1 expression. (liu2023functionalidentificationof pages 1-2, gu2024visualizationofargininosuccinate pages 1-2) • Brain (CNS) — target of ammonia toxicity; edema/seizure risk during hyperammonemia. (alshaya2018intravenousandoral pages 1-2, simpson2025ureacycledisorders pages 1-4)

3.5 Cellular components (GO Cellular Component)

• Cytosol — ASS1 is described as a cytosolic enzyme. (gu2024visualizationofargininosuccinate pages 1-2, liu2023functionalidentificationof pages 1-2)

  1. Biological processes disrupted (GO-oriented mapping)

Primary disrupted processes: • Urea cycle / ureagenesis / nitrogen compound metabolic process — reduced conversion of waste nitrogen to urea due to ASS1 deficiency. (liu2023functionalidentificationof pages 1-2, gu2024visualizationofargininosuccinate pages 1-2) • Citrulline metabolic process / arginine biosynthetic process (urea-cycle dependent) — decreased arginine availability and citrulline accumulation at the ASS1 step. (liu2023functionalidentificationof pages 1-2, gu2024visualizationofargininosuccinate pages 2-4)

Downstream brain processes affected during crises: • Ammonia detoxification to glutamine in astrocytes (part of glutamine biosynthetic process) — mechanistically linked to osmotic stress and edema. (alshaya2018intravenousandoral pages 1-2) • Cellular osmotic stress response / cell swelling → cerebral edema cascade (pathophysiologic mechanism described clinically). (alshaya2018intravenousandoral pages 1-2)

  1. Disease progression: sequence from trigger to clinical manifestations

5.1 Initial trigger: genetic loss-of-function in ASS1

Inherited ASS1 variants reduce ASS1 protein abundance and/or enzymatic activity, causing a constitutive reduction of hepatic ureagenesis capacity. Recent functional studies identify variants that decrease ASS1 at protein and transcription levels and demonstrate markedly reduced enzyme activity for truncating or in-frame coding variants. (liu2023functionalidentificationof pages 1-2)

5.2 Metabolic decompensation: nitrogen load and catabolic stress

Although baseline impairment exists, acute hyperammonemic crises are commonly precipitated when nitrogen production exceeds residual detoxification capacity (e.g., illness/catabolism), producing abrupt rises in ammonia and citrulline. (alshaya2018intravenousandoral pages 1-2, simpson2025ureacycledisorders pages 1-4)

5.3 CNS injury: ammonia entry into brain → astrocytic glutamine accumulation → edema

As ammonia rises systemically, it crosses into the CNS and is converted to glutamine in astrocytes. Rapid glutamine accumulation drives osmotic swelling, inflammatory cascades, and cerebral edema, producing encephalopathy (lethargy → seizures → coma). (alshaya2018intravenousandoral pages 1-2, karachanakyankova2024rarepathogenicvariants pages 5-7)

  1. Phenotypic manifestations and their mechanistic links (HP-oriented)

Key clinical phenotypes described in recent literature include: • Hyperammonemia (biochemical) and encephalopathy: neonatal acute form with “hyperammonemia, progressive lethargy, poor feeding, vomiting and signs of increased intracranial pressure.” (karachanakyankova2024rarepathogenicvariants pages 5-7) • Seizures/convulsions during crises and evolving neurologic injury. (gu2024visualizationofargininosuccinate pages 1-2, simpson2025ureacycledisorders pages 1-4) • Chronic/late-onset phenotypes: intermittent hyperammonemia, developmental delay, and neurocognitive impairment consistent with cumulative or early irreversible injury. (karachanakyankova2024rarepathogenicvariants pages 5-7)

  1. Recent developments and latest research (prioritizing 2023–2024)

7.1 Variant interpretation and structure-function (2023–2024)

• 2023 functional validation studies have expanded pathogenic ASS1 variant spectra and demonstrated that some non-coding variants can be hypomorphic by reducing expression, linking genotype to residual activity. (liu2023functionalidentificationof pages 1-2) • 2024 structural/in silico analysis emphasizes the importance of C-terminal structural elements for oligomer/tetramer stability, supporting a mechanistic explanation for loss of function in specific deletion-insertion variants. (gu2024visualizationofargininosuccinate pages 1-2)

7.2 RNA therapeutics and mRNA approaches (2024)

A 2024 authoritative review of RNA therapeutics for UCDs notes that “LNP-formulated mRNA therapy has been assayed preclinically for citrullinemia type I (CTLN1),” positioning liver-targeted RNA delivery as an emerging disease-modifying strategy beyond diet and scavengers. (richard2024exploringrnatherapeutics pages 1-2)

The same review provides an actionable genetic insight: nonsense mutations occur in a minority of UCD genes, including “~7–10%” for ASS1 among others, highlighting a defined subset potentially addressable by suppressor-tRNA or readthrough-style RNA approaches. (richard2024exploringrnatherapeutics pages 1-2)

7.3 Contemporary evaluation of liver transplantation (2024)

A 2024 Genetics in Medicine study provides severity-adjusted comparative outcomes for liver transplantation (LTx) vs medical management across UCDs including CTLN1. LTx was associated with sustained metabolic stability and “prevention of further [hyperammonemic events] after transplantation,” along with “liberalization of protein intake,” and the conclusion that LTx provides metabolic stability “without further need of protein restriction or nitrogen-scavenging therapy.” (posset2024severityadjustedevaluationof pages 1-2, posset2024severityadjustedevaluationof pages 8-9)

However, neurocognitive outcomes did not improve compared with medically managed counterparts; one interpretation is that neurocognitive impairment can reflect irreversible early injury related to NH4+max and early crisis severity. (posset2024severityadjustedevaluationof pages 1-2, posset2024severityadjustedevaluationof pages 8-9)

  1. Current applications and real-world implementations

8.1 Newborn screening and early detection

Real-world registry evidence indicates that early diagnosis through newborn screening can improve survival and reduce neurological impairment in UCDs. In the Spanish UCD registry analysis (cases up to Feb 2024; published 2025), only 10.6% were diagnosed via newborn screening, yet diagnosis via NBS was associated with improved survival and reduced neurologic impairment. (martinhernandez2025understandingthenatural pages 2-3)

8.2 Acute hyperammonemia management (practice thresholds and interventions)

A clinical “survival guide” type resource (2024) summarizes operational thresholds and acute actions used in practice, including: “Stop protein intake (for a maximum 48 hours).” and dialysis escalation when “blood NH4+ escalates to >500 μmol/L” (continuous renal replacement therapy). It also provides common dosing ranges for IV nitrogen scavengers and arginine intermediates and distinguishes normal vs suspicious ammonia thresholds (e.g., suspect IEM >200 μmol/L in neonates). (yin2024asurvivalguide pages 16-19)

Mechanistic rationale for emergent management is grounded in the astrocyte/glutamine edema model described above. (alshaya2018intravenousandoral pages 1-2)

8.3 Long-term medical management

Long-term management for CTLN1 and other UCDs centers on protein-restricted nutrition with essential amino-acid support and nitrogen scavengers (benzoate/phenylbutyrate formulations) plus arginine/citrulline supplementation tailored to the specific enzyme defect. These principles are summarized in the transplantation comparative study background and in practical clinical guidance. (posset2024severityadjustedevaluationof pages 1-2, yin2024asurvivalguide pages 16-19)

8.4 Liver transplantation

LTx is currently the only established “curative” intervention at the metabolic level for hepatic ureagenesis defects. In a large modern analysis, transplant programs show “overall 5-year patient survival rate of over 90% and a 5-year graft survival rate of over 85%.” (posset2024severityadjustedevaluationof pages 1-2, posset2024severityadjustedevaluationof pages 2-4)

  1. Relevant statistics and data (recent)

9.1 Registry outcomes (Spain; cases through Feb 2024; published 2025)

In the Spanish UCD registry update (n=255 UCD patients), outcomes included: • Global mortality: 14.9%. (martinhernandez2025understandingthenatural pages 2-3) • Early-onset vs late-onset mortality: 35.8% vs 7.1%. (martinhernandez2025understandingthenatural pages 2-3) • Neurological impairment: 44% of patients. (martinhernandez2025understandingthenatural pages 2-3) • Diagnostic ammonia as a prognostic marker: median ammonia in deceased patients 1058 μmol/L (IQR 410–1793) vs 294 μmol/L (IQR 71–494) in survivors. (martinhernandez2025understandingthenatural pages 2-3) • Liver transplantation performed in 20.6% with survival 95.2%. (martinhernandez2025understandingthenatural pages 2-3)

9.2 Severity-adjusted transplant analysis (2024)

In Posset et al. (2024), liver transplantation eliminated hyperammonemic events post-transplant (mean HAEs 0.00 post-LTx in both severe and attenuated groups), while pre-LTx patients had higher HAE rates than medically managed peers (consistent with confounding-by-indication and/or modifying factors). (posset2024severityadjustedevaluationof pages 4-6)

  1. Expert opinions and authoritative synthesis

Across authoritative sources, a convergent expert view emerges: • CTLN1 is fundamentally a liver-based cytosolic ureagenesis defect, but its morbidity/mortality is dominated by acute brain injury during hyperammonemic crises via astrocyte glutamine-mediated edema. (alshaya2018intravenousandoral pages 1-2, liu2023functionalidentificationof pages 1-2) • Prevention of hyperammonemic events is a primary therapeutic goal; however, neurocognitive outcomes may not normalize even with definitive hepatic correction (transplantation), supporting the concept of early irreversible injury and emphasizing the value of rapid diagnosis and early crisis avoidance. (posset2024severityadjustedevaluationof pages 1-2, martinhernandez2025understandingthenatural pages 2-3) • Next-generation therapeutics are shifting toward liver-targeted gene/RNA modalities; notably, LNP mRNA therapy has already been tested preclinically for CTLN1, indicating a plausible route for future disease modification without transplantation. (richard2024exploringrnatherapeutics pages 1-2)

  1. Knowledge-base–ready annotation block (structured)

11.1 Pathophysiology description (narrative)

Citrullinemia type I is caused by biallelic loss of argininosuccinate synthase 1 (ASS1), a cytosolic periportal-hepatocyte urea-cycle enzyme that catalyzes citrulline + aspartate → argininosuccinate. Enzyme deficiency blocks ureagenesis, producing hyperammonemia, citrullinemia, hypocitrulline-to-arginine conversion with low arginine, and orotic aciduria. During catabolic stress, systemic ammonia rises and enters the CNS, where astrocytes detoxify ammonia to glutamine; rapid intracellular glutamine accumulation raises osmolarity, inducing astrocyte swelling, inflammatory cascades, and cerebral edema with seizures, coma, and risk of death. Residual ASS1 activity and variant structural impacts (citrulline binding vs oligomerization/tetramer stability) contribute to the severity continuum from classic neonatal-onset to late-onset presentations.

11.2 Ontology-style entities

Genes (HGNC): • ASS1 (argininosuccinate synthase 1). (liu2023functionalidentificationof pages 1-2)

Biological Processes (GO; representative): • Urea cycle / ureagenesis (nitrogen disposal). (liu2023functionalidentificationof pages 1-2) • Citrulline metabolic process / arginine biosynthesis (urea-cycle dependent). (liu2023functionalidentificationof pages 1-2) • Glutamine biosynthetic process in astrocytes during ammonia detoxification (mechanistic). (alshaya2018intravenousandoral pages 1-2)

Cellular Components (GO CC): • Cytosol (ASS1 localization). (gu2024visualizationofargininosuccinate pages 1-2, liu2023functionalidentificationof pages 1-2)

Cell Types (CL; representative): • Hepatocyte (periportal hepatocyte emphasis). (liu2023functionalidentificationof pages 1-2) • Astrocyte. (alshaya2018intravenousandoral pages 1-2)

Anatomy (UBERON; representative): • Liver; periportal zone. (liu2023functionalidentificationof pages 1-2) • Brain/CNS. (alshaya2018intravenousandoral pages 1-2)

Phenotypes (HP; representative, text-mapped): • Hyperammonemia; encephalopathy; lethargy; seizures; cerebral edema/increased intracranial pressure; developmental delay/intellectual disability. (karachanakyankova2024rarepathogenicvariants pages 5-7, alshaya2018intravenousandoral pages 1-2)

Chemicals (ChEBI; representative): • Ammonia; citrulline; arginine; aspartate; glutamine; orotic acid; benzoate; phenylbutyrate/glycerol phenylbutyrate. (alshaya2018intravenousandoral pages 1-2, liu2023functionalidentificationof pages 1-2, posset2024severityadjustedevaluationof pages 1-2)

11.3 Evidence items (PMID/DOI/URL)

Because PMIDs were not available in the tool metadata for several key 2023–2024 sources, the evidence list includes DOI and URL (both are stable identifiers). If PMIDs are required for downstream ingestion, a separate PubMed lookup step is recommended.

Key mechanistic/definition sources: • Liu et al., Frontiers in Genetics (Jul 2023). DOI: 10.3389/fgene.2023.1172947. URL: https://doi.org/10.3389/fgene.2023.1172947 (liu2023functionalidentificationof pages 1-2) • Gu et al., Frontiers in Molecular Biosciences (Nov 2024). DOI: 10.3389/fmolb.2024.1482773. URL: https://doi.org/10.3389/fmolb.2024.1482773 (gu2024visualizationofargininosuccinate pages 1-2)

Neurotoxicity mechanism: • Alshaya et al., Current Emergency and Hospital Medicine Reports (Oct 2018). DOI: 10.1007/s40138-018-0174-5. URL: https://doi.org/10.1007/s40138-018-0174-5 (alshaya2018intravenousandoral pages 1-2)

Emerging therapies: • Richard et al., Journal of Inherited Metabolic Disease (Oct 2024). DOI: 10.1002/jimd.12807. URL: https://doi.org/10.1002/jimd.12807 (richard2024exploringrnatherapeutics pages 1-2)

Transplant outcomes: • Posset et al., Genetics in Medicine (Apr 2024). DOI: 10.1016/j.gim.2023.101039. URL: https://doi.org/10.1016/j.gim.2023.101039 (posset2024severityadjustedevaluationof pages 1-2)

Registry statistics: • Martín-Hernández et al., Nutrients (Mar 2025; includes cases through Feb 2024). DOI: 10.3390/nu17071173. URL: https://doi.org/10.3390/nu17071173 (martinhernandez2025understandingthenatural pages 2-3)

Case quantitative labs (image-supported): • Gu et al. 2024 CTLN1 case ammonia/citrulline values (cropped text image). (gu2024visualizationofargininosuccinate media 3a7cd48b)

Limitations and gaps in this run

• MONDO ID could not be verified from retrieved full texts. • Several high-value clinical guidance documents (e.g., GeneReviews “Classic Citrullinemia” 2024) were not obtainable in-tool for full-text extraction; consequently, some classic guideline statements were supported instead by accessible peer-reviewed sources and a practice-oriented “survival guide” document. • PMIDs were not consistently available in the retrieved metadata for 2023–2024 papers; DOI/URL-based referencing is provided.

References

  1. (liu2023functionalidentificationof pages 1-2): Jing Liu, Zhongjie Wang, Huiming Yan, Yanling Teng, Qingxin Shi, Jing Chen, Wanglan Tang, Wenxian Yu, Ying Peng, Hui Xi, Na Ma, Desheng Liang, Zhuo Li, and Lingqian Wu. Functional identification of two novel variants and a hypomorphic variant in ass1 from patients with citrullinemia type i. Frontiers in Genetics, Jul 2023. URL: https://doi.org/10.3389/fgene.2023.1172947, doi:10.3389/fgene.2023.1172947. This article has 5 citations and is from a peer-reviewed journal.

  2. (gu2024visualizationofargininosuccinate pages 1-2): Xia Gu, Wenhui Mo, Guiying Zhuang, Congcong Shi, Tao Wei, Jinze Zhang, Chiaowen Tu, Yao Cai, Biwen Liao, and Hu Hao. Visualization of argininosuccinate synthetase by in silico analysis: novel insights into citrullinemia type i disorders. Frontiers in Molecular Biosciences, Nov 2024. URL: https://doi.org/10.3389/fmolb.2024.1482773, doi:10.3389/fmolb.2024.1482773. This article has 0 citations.

  3. (gu2024visualizationofargininosuccinate pages 2-4): Xia Gu, Wenhui Mo, Guiying Zhuang, Congcong Shi, Tao Wei, Jinze Zhang, Chiaowen Tu, Yao Cai, Biwen Liao, and Hu Hao. Visualization of argininosuccinate synthetase by in silico analysis: novel insights into citrullinemia type i disorders. Frontiers in Molecular Biosciences, Nov 2024. URL: https://doi.org/10.3389/fmolb.2024.1482773, doi:10.3389/fmolb.2024.1482773. This article has 0 citations.

  4. (gu2024visualizationofargininosuccinate media 3a7cd48b): Xia Gu, Wenhui Mo, Guiying Zhuang, Congcong Shi, Tao Wei, Jinze Zhang, Chiaowen Tu, Yao Cai, Biwen Liao, and Hu Hao. Visualization of argininosuccinate synthetase by in silico analysis: novel insights into citrullinemia type i disorders. Frontiers in Molecular Biosciences, Nov 2024. URL: https://doi.org/10.3389/fmolb.2024.1482773, doi:10.3389/fmolb.2024.1482773. This article has 0 citations.

  5. (karachanakyankova2024rarepathogenicvariants pages 5-7): Sena Karachanak-Yankova, Dimitar Serbezov, Georgi Antov, Mikaela Stancheva, Marta Mihaylova, Savina Hadjidekova, Draga Toncheva, Anastas Pashov, Diyana Belejanska, Yavor Zhelev, Mariya Petrova, Shima Mehrabian, and Latchezar Traykov. Rare pathogenic variants in pooled whole-exome sequencing data suggest hyperammonemia as a possible cause of dementia not classified as alzheimer’s disease or frontotemporal dementia. Genes, 15:753, Jun 2024. URL: https://doi.org/10.3390/genes15060753, doi:10.3390/genes15060753. This article has 2 citations.

  6. (alshaya2018intravenousandoral pages 1-2): Abdulrahman Alshaya, John Fanikos, and Elizabeth DeMaio. Intravenous and oral hyperammonemia management. Current Emergency and Hospital Medicine Reports, 6:182-193, Oct 2018. URL: https://doi.org/10.1007/s40138-018-0174-5, doi:10.1007/s40138-018-0174-5. This article has 0 citations.

  7. (simpson2025ureacycledisorders pages 1-4): KL Simpson, EL MacLeod, and A Kakajiwala. Urea cycle disorders overview. Unknown journal, 2025.

  8. (yin2024asurvivalguide pages 16-19): LH YIN. A survival guide a survival guide. Unknown journal, 2024.

  9. (posset2024severityadjustedevaluationof pages 1-2): Roland Posset, Sven F. Garbade, Florian Gleich, Svenja Scharre, Jürgen G. Okun, Andrea L. Gropman, Sandesh C.S. Nagamani, Ann-Catrin Druck, Friederike Epp, Georg F. Hoffmann, Stefan Kölker, Matthias Zielonka, Nicholas Ah Mew, Jennifer Seminara, Lindsay C. Burrage, Gerard T. Berry, Margo Breilyn, Andreas Schulze, Cary O. Harding, Susan A. Berry, Derek Wong, Shawn E. McCandless, Matthias R. Baumgartner, Laura Konczal, Can Ficicioglu, George A. Diaz, Curtis R. Coughlin, Gregory M. Enns, Renata C. Gallagher, Christina Lam, Tamar Stricker, Greta Wilkening, Carlo Dionisi-Vici, Dries Dobbelaere, Javier Blasco-Alonso, Alberto B. Burlina, Peter Freisinger, Peter M. van Hasselt, Anastasia Skouma, Allan M. Lund, Roshni Vara, Adrijan Sarajlija, Andrew A. Morris, Anupam Chakrapani, Ivo Barić, Persephone Augoustides-Savvopoulou, Yin-Hsiu Chien, Elisenda Cortès-Saladelafont, Francois Eyskens, Gwendolyn Gramer, Jiri Zeman, Daniela Karall, Maria L. Couce, Chris Mühlhausen, Consuelo Pedrón-Giner, Ute Spiekerkoetter, Jolanta Sykut-Cegielska, Margreet Wagenmakers, and Frits A. Wijburg. Severity-adjusted evaluation of liver transplantation on health outcomes in urea cycle disorders. Genetics in Medicine, 26:101039, Apr 2024. URL: https://doi.org/10.1016/j.gim.2023.101039, doi:10.1016/j.gim.2023.101039. This article has 11 citations and is from a highest quality peer-reviewed journal.

  10. (richard2024exploringrnatherapeutics pages 1-2): Eva Richard, Ainhoa Martínez‐Pizarro, and Lourdes R. Desviat. Exploring rna therapeutics for urea cycle disorders. Journal of Inherited Metabolic Disease, 47:1269-1277, Oct 2024. URL: https://doi.org/10.1002/jimd.12807, doi:10.1002/jimd.12807. This article has 4 citations and is from a peer-reviewed journal.

  11. (posset2024severityadjustedevaluationof pages 8-9): Roland Posset, Sven F. Garbade, Florian Gleich, Svenja Scharre, Jürgen G. Okun, Andrea L. Gropman, Sandesh C.S. Nagamani, Ann-Catrin Druck, Friederike Epp, Georg F. Hoffmann, Stefan Kölker, Matthias Zielonka, Nicholas Ah Mew, Jennifer Seminara, Lindsay C. Burrage, Gerard T. Berry, Margo Breilyn, Andreas Schulze, Cary O. Harding, Susan A. Berry, Derek Wong, Shawn E. McCandless, Matthias R. Baumgartner, Laura Konczal, Can Ficicioglu, George A. Diaz, Curtis R. Coughlin, Gregory M. Enns, Renata C. Gallagher, Christina Lam, Tamar Stricker, Greta Wilkening, Carlo Dionisi-Vici, Dries Dobbelaere, Javier Blasco-Alonso, Alberto B. Burlina, Peter Freisinger, Peter M. van Hasselt, Anastasia Skouma, Allan M. Lund, Roshni Vara, Adrijan Sarajlija, Andrew A. Morris, Anupam Chakrapani, Ivo Barić, Persephone Augoustides-Savvopoulou, Yin-Hsiu Chien, Elisenda Cortès-Saladelafont, Francois Eyskens, Gwendolyn Gramer, Jiri Zeman, Daniela Karall, Maria L. Couce, Chris Mühlhausen, Consuelo Pedrón-Giner, Ute Spiekerkoetter, Jolanta Sykut-Cegielska, Margreet Wagenmakers, and Frits A. Wijburg. Severity-adjusted evaluation of liver transplantation on health outcomes in urea cycle disorders. Genetics in Medicine, 26:101039, Apr 2024. URL: https://doi.org/10.1016/j.gim.2023.101039, doi:10.1016/j.gim.2023.101039. This article has 11 citations and is from a highest quality peer-reviewed journal.

  12. (martinhernandez2025understandingthenatural pages 2-3): Elena Martín-Hernández, Marcello Bellusci, Patricia Pérez-Mohand, Patricia Correcher Medina, Javier Blasco-Alonso, Ana Morais-López, Javier de las Heras, Silvia María Meavilla Olivas, Lucy Dougherty-de Miguel, Maria Luz Couce, Elvira Cañedo Villarroya, María Concepción García Jiménez, Pedro Juan Moreno-Lozano, Inmaculada Vives, Mercedes Gil-Campos, Sinziana Stanescu, Leticia Ceberio-Hualde, María Camprodón, Elisenda Cortès-Saladelafont, Rafael López-Urdiales, Mercedes Murray Hurtado, Ana María Márquez Armenteros, Concha Sierra Córcoles, Luis Peña-Quintana, Mónica Ruiz-Pons, Carlos Alcalde, Fernando Castellanos-Pinedo, Elena Dios, Delia Barrio-Carreras, María Martín-Cazaña, Mónica García-Peris, José David Andrade, Camila García-Volpe, Mariela de los Santos, Angels García-Cazorla, Mireia del Toro, Ana Felipe-Rucián, María José Comino Monroy, Paula Sánchez-Pintos, Ana Matas, David Gil Ortega, Álvaro Martín-Rivada, Ana Bergua, Amaya Belanger-Quintana, Isidro Vitoria, Raquel Yahyaoui, Belén Pérez, Montserrat Morales-Conejo, and Pilar Quijada-Fraile. Understanding the natural history and the effects of current therapeutic strategies on urea cycle disorders: insights from the ucd spanish registry. Nutrients, 17:1173, Mar 2025. URL: https://doi.org/10.3390/nu17071173, doi:10.3390/nu17071173. This article has 0 citations.

  13. (posset2024severityadjustedevaluationof pages 2-4): Roland Posset, Sven F. Garbade, Florian Gleich, Svenja Scharre, Jürgen G. Okun, Andrea L. Gropman, Sandesh C.S. Nagamani, Ann-Catrin Druck, Friederike Epp, Georg F. Hoffmann, Stefan Kölker, Matthias Zielonka, Nicholas Ah Mew, Jennifer Seminara, Lindsay C. Burrage, Gerard T. Berry, Margo Breilyn, Andreas Schulze, Cary O. Harding, Susan A. Berry, Derek Wong, Shawn E. McCandless, Matthias R. Baumgartner, Laura Konczal, Can Ficicioglu, George A. Diaz, Curtis R. Coughlin, Gregory M. Enns, Renata C. Gallagher, Christina Lam, Tamar Stricker, Greta Wilkening, Carlo Dionisi-Vici, Dries Dobbelaere, Javier Blasco-Alonso, Alberto B. Burlina, Peter Freisinger, Peter M. van Hasselt, Anastasia Skouma, Allan M. Lund, Roshni Vara, Adrijan Sarajlija, Andrew A. Morris, Anupam Chakrapani, Ivo Barić, Persephone Augoustides-Savvopoulou, Yin-Hsiu Chien, Elisenda Cortès-Saladelafont, Francois Eyskens, Gwendolyn Gramer, Jiri Zeman, Daniela Karall, Maria L. Couce, Chris Mühlhausen, Consuelo Pedrón-Giner, Ute Spiekerkoetter, Jolanta Sykut-Cegielska, Margreet Wagenmakers, and Frits A. Wijburg. Severity-adjusted evaluation of liver transplantation on health outcomes in urea cycle disorders. Genetics in Medicine, 26:101039, Apr 2024. URL: https://doi.org/10.1016/j.gim.2023.101039, doi:10.1016/j.gim.2023.101039. This article has 11 citations and is from a highest quality peer-reviewed journal.

  14. (posset2024severityadjustedevaluationof pages 4-6): Roland Posset, Sven F. Garbade, Florian Gleich, Svenja Scharre, Jürgen G. Okun, Andrea L. Gropman, Sandesh C.S. Nagamani, Ann-Catrin Druck, Friederike Epp, Georg F. Hoffmann, Stefan Kölker, Matthias Zielonka, Nicholas Ah Mew, Jennifer Seminara, Lindsay C. Burrage, Gerard T. Berry, Margo Breilyn, Andreas Schulze, Cary O. Harding, Susan A. Berry, Derek Wong, Shawn E. McCandless, Matthias R. Baumgartner, Laura Konczal, Can Ficicioglu, George A. Diaz, Curtis R. Coughlin, Gregory M. Enns, Renata C. Gallagher, Christina Lam, Tamar Stricker, Greta Wilkening, Carlo Dionisi-Vici, Dries Dobbelaere, Javier Blasco-Alonso, Alberto B. Burlina, Peter Freisinger, Peter M. van Hasselt, Anastasia Skouma, Allan M. Lund, Roshni Vara, Adrijan Sarajlija, Andrew A. Morris, Anupam Chakrapani, Ivo Barić, Persephone Augoustides-Savvopoulou, Yin-Hsiu Chien, Elisenda Cortès-Saladelafont, Francois Eyskens, Gwendolyn Gramer, Jiri Zeman, Daniela Karall, Maria L. Couce, Chris Mühlhausen, Consuelo Pedrón-Giner, Ute Spiekerkoetter, Jolanta Sykut-Cegielska, Margreet Wagenmakers, and Frits A. Wijburg. Severity-adjusted evaluation of liver transplantation on health outcomes in urea cycle disorders. Genetics in Medicine, 26:101039, Apr 2024. URL: https://doi.org/10.1016/j.gim.2023.101039, doi:10.1016/j.gim.2023.101039. This article has 11 citations and is from a highest quality peer-reviewed journal.